rs16944 [16-18]. However, this association was not confirmed in other studies [19,20]. Furthermore, none of the previous studies in Asian populations have obtained evidence for an association between *IL-1β* gene and schizophrenia [21-23]. All of the aforementioned association studies, except for that of Shirts, et al. [19], examined only rs16944 and/or rs1143634. Therefore, the role of other *IL-1β* gene polymorphisms remains to be determined. We here examined 5 tagging polymorphisms of the *IL-1β* gene for an association with schizophrenia in a Japanese sample.

Methods

Subjects

Subjects were 533 patients with schizophrenia (302 males: mean age ± standard deviation 43.4 ± 13.0 years; 233 females; mean age 44.8 ± 15.3 years) and 1136 healthy controls (388 males: mean age 44.6 ± 17.3 years; 748 females; 46.3 ± 15.6 years). The mean age at onset was 23.9 ± 8.0 and 25.8 ± 9.8 years for male and female patients, respectively. All subjects were biologically unrelated Japanese individuals, based on their self-reports, and were recruited from the outpatient clinic of the National Center of Neurology and Psychiatry Hospital, Tokyo, Japan or through advertisements in free local information magazines and by our website announcement. Consensus diagnosis by at least two psychiatrists was made for each patient according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition criteria [24], on the basis of unstructured interviews and information from medical records. The controls were healthy volunteers with no current or past history of psychiatric treatment, and were screened using the Japanese version of the Mini International Neuropsychiatric Interview (M.I.N.I.) [25,26] by a research psychiatrist to rule out any axis I psychiatric disorders. Participants were excluded if they had prior medical histories of central nervous system disease or severe head injury, or if they met the criteria for substance abuse or dependence, or mental retardation. The study protocol was approved by the ethics committee at the National Center of Neurology and Psychiatry, Japan. After description of the study, written informed consent was obtained from every subject. Most of the subjects had participated in our previous genetic association studies [27,28]. Some of the control subjects had also participated in our previous studies which examined *IL-1β* gene polymorphisms [29,30].

Genotyping

Five tagging single nucleotide polymorphisms (SNPs) (rs2853550, rs1143634, rs1143633, rs1143630, rs16944) in a region 1 kilobase (kb) upstream to 1 kb downstream of the *IL-1β* gene (chromosome 2: 113,302,808 - 113,311,827 bp) were selected by Haploview 4.2 [31]

using Japanese and Chinese population in the HapMap SNP set (version 22), at an r^2 threshold of 0.80 with a minor allele frequency greater than 0.1. Genomic DNA was prepared from the venous blood according to standard procedures. The SNPs were genotyped using the TaqMan 5'-exonuclease allelic discrimination assay. Thermal cycling conditions for polymerase chain reaction were 1 cycle at 95°C for 10 minutes followed by 50 cycles of 92°C for 15 seconds and 60°C for 1 minute. The allele-specific fluorescence was measured with ABI PRISM 7900 Sequence Detection Systems (Applied Biosystems, Foster city, CA, USA). Genotype data were read blind to the case-control status. Ambiguous genotype data were not included in the analysis. The call rates for each SNP ranged from 97.7% to 98.6%. The genotyping failure rate for all SNPs combined was < 2%. In 92 subjects, all 5 SNPs were genotyped in duplicate to ensure genotyping accuracy, and the concordance rate of called genotypes was over 99%.

Statistical analysis

Deviations of genotype distributions from the Hardy-Weinberg equilibrium (HWE) were assessed with the exact test described by Wigginton et al [32]. Genotype and allele distributions were compared between patients and controls by using the χ^2 test for independence or with Fisher's exact test. The above statistical analyses were performed using PLINK version 1.07 [33].

Haploview 4.2 [31] was used to estimate haplotype frequencies and linkage disequilibrium (LD) coefficients. Haplotypes with frequencies > 1% were included in the association analysis. Permutation procedure (10,000 replications) was used to determine the empirical significance.

Statistical tests were two tailed and statistical significance was considered when $P < 0.05$. Significance level corrected for multiple comparisons of 5 SNPs was set at $P < 0.013$ by a method proposed by Li et al [34], which was calculated using SNPSpD (SNP Spectral Decomposition) software [35].

Power calculations were performed using the Power Calculator for Two Stage Association Studies (http://www.sph.umich.edu/csg/abecasis/CaTS/). Power was calculated under prevalence of 0.01 using an allelic model with an alpha level of 0.05. Assuming disease allele frequencies of 0.20 and 0.40, our sample had 80% statistical power to detect relative risks of 1.28 and 1.23, respectively. Similarly, we had 90% power to detect relative risks of 1.33 and 1.27.

Since several aspects of immunity have marked sex differences [36], analyses were performed not only for the entire sample but also for each gender separately. Assuming allele frequency of 0.40, male and female samples each had 80% statistical power to detect relative risks of 1.35 and 1.34, respectively.

Table 1 Association analysis of the 5 SNPs in both genders combined

SNP name	Allele 1/2		N	Genotype			Allele		P-value		HWE P-value
				1/1	1/2	2/2	1	2	Genotype	Allele	
rs2853550	A/G	Schizophrenia	531	9	128	394	146	916	0.23	0.088	0.86
				(0.02)	(0.24)	(0.74)	(0.14)	(0.86)			
		Controls	1115	14	232	869	260	1970			0.88
				(0.01)	(0.21)	(0.78)	(0.12)	(0.88)			
rs1143634	A/G	Schizophrenia	525	1	41	483	43	1007	0.97[a]	0.90	0.59
				(0.00)	(0.08)	(0.92)	(0.04)	(0.96)			
		Controls	1121	2	90	1029	94	2148	1.00		
				(0.00)	(0.08)	(0.92)	(0.04)	(0.96)			
rs1143633	C/T	Schizophrenia	524	111	249	164	471	577	0.035	0.0089	0.38
				(0.21)	(0.48)	(0.31)	(0.45)	(0.55)			
		Controls	1123	188	525	410	901	1345			0.38
				(0.17)	(0.47)	(0.37)	(0.40)	(0.60)			
rs1143630	T/G	Schizophrenia	520	13	140	367	166	874	0.88	0.66	1.00
				(0.03)	(0.27)	(0.71)	(0.16)	(0.84)			
		Controls	1119	24	296	799	344	1894			0.65
				(0.02)	(0.26)	(0.71)	(0.15)	(0.85)			
rs16944	A/G	Schizophrenia	521	123	253	145	499	543	0.18	0.060	0.54
				(0.24)	(0.49)	(0.28)	(0.48)	(0.52)			
		Controls	1111	226	534	351	986	1236			0.39
				(0.20)	(0.48)	(0.32)	(0.44)	(0.56)			

(a) Calculated using Fisher's exact test.
SNP: single nucleotide polymorphism; HWE: Hardy-Weinberg Disequilibrium
Numbers in parentheses represent the frequencies of genotypes and alleles.

Results

Genotype and allele distributions of the examined SNPs for the entire sample, males, and females are shown in Table 1, 2, and 3, respectively. The genotype distributions did not significantly deviate from the HWE in any of the SNPs examined. Significant differences in genotype and allele distributions were found between the patients with schizophrenia and controls for rs1143633. The C allele was significantly more common in patients than in controls (odds ratio 1.22, 95% confidence interval (CI) 1.05 to 1.41, P = 0.0089). This association remained significant after correcting for multiple testing of 5 SNPs (corrected P = 0.013). When the analysis was performed separately in each gender, significant difference between patients and controls in allele distribution of rs1143633 was observed only in females (odds ratio 1.34, 95% CI 1.08 to 1.66, P = 0.0073). The A allele of rs16944 also showed a trend towards association with schizophrenia in female subjects (odds ratio 1.26, 95% CI 1.02 to 1.56, P = 0.032).

Linkage disequilibrium (LD) coefficients (D' and r^2) and haplotype blocks are shown in Figure 1. Results of the haplotype association analyses are shown in Table 4. No significant difference in haplotype distribution was found between patients with schizophrenia and controls (all P > 0.05 by permutation test).

Discussion

To our knowledge, the present study is the largest study to date that examined the *IL-1β* gene polymorphisms for association with schizophrenia. The results provide the first evidence suggesting that the C allele of rs1143633 is associated with schizophrenia.

The study in a United States population by Shirts et al [19] was the only one that previously examined the association of schizophrenia with rs1143633, in which no significant difference was found in allele frequencies between patients and controls. Although Watanabe et al [23] have also examined 9 SNPs of the IL-1 gene complex in Japanese subjects, none of the SNPs examined in their study was in remarkable linkage disequilibrium with rs1143633 or rs16944 (all r^2 < 0.1 based on HapMap Japanese and Han Chinese population data, release 22). The inconsistent results regarding the effect of rs1143633 between Shirts, et al [19] and our study may be attributable to ethnic difference. Indeed, a recent meta-analysis has shown a significant association of the G allele of rs16944 and the G allele carrier status of rs1143634 with a risk of schizophrenia in Caucasian, but not in Asian, populations [37]. Our samples provided sufficient power to detect relatively small relative risks, and therefore suggest that rs16944 and rs1143634 have no major effect on

Table 2 Association analysis of the 5 SNPs in males

SNP name	Allele 1/2		N	Males							HWE P-value
				Genotype			Allele		P-value		
				1/1	1/2	2/2	1	2	Genotype	Allele	
rs2853550	A/G	Schizophrenia	300	4	74	222	82	518	0.68[a]	0.69	0.62
				(0.01)	(0.25)	(0.74)	(0.14)	(0.86)			
		Controls	383	7	85	291	99	667			0.82
				(0.02)	(0.22)	(0.76)	(0.13)	(0.87)			
rs1143634	A/G	Schizophrenia	298	0	24	274	24	572	0.81[a]	0.82	1.00
				(0.00)	(0.08)	(0.92)	(0.04)	(0.96)			
		Controls	383	1	27	355	29	737			0.42
				(0.00)	(0.07)	(0.93)	(0.04)	(0.96)			
rs1143633	C/T	Schizophrenia	299	59	145	95	263	335	0.43	0.47	0.81
				(0.20)	(0.48)	(0.32)	(0.44)	(0.56)			
		Controls	383	77	168	138	322	444			0.059
				(0.20)	(0.44)	(0.36)	(0.42)	(0.58)			
rs1143630	T/G	Schizophrenia	295	7	81	207	95	495	0.75	0.73	1.00
				(0.02)	(0.27)	(0.70)	(0.16)	(0.84)			
		Controls	383	6	106	271	118	648			0.32
				(0.02)	(0.28)	(0.71)	(0.15)	(0.85)			
rs16944	A/G	Schizophrenia	295	66	143	86	275	315	0.92	0.67	0.64
				(0.22)	(0.48)	(0.29)	(0.47)	(0.53)			
		Controls	385	82	186	117	350	420			0.61
				(0.21)	(0.48)	(0.30)	(0.45)	(0.55)			

(a) Calculated using Fisher's exact test.
SNP: single nucleotide polymorphism; HWE: Hardy-Weinberg Disequilibrium
Numbers in parentheses represent the frequencies of genotypes and alleles.

Table 3 Association analysis of the 5 SNPs in females

SNP name	Allele 1/2		N	Males							HWE P-value
				Genotype			Allele		P-value		
				1/1	1/2	2/2	1	2	Genotype	Allele	
rs2853550	A/G	Schizophrenia	231	5	54	172	64	398	0.18	0.096	0.78
				(0.02)	(0.23)	(0.74)	(0.14)	(0.86)			
		Controls	732		7	147	578		161	1303	0.57
				(0.01)	(0.20)	(0.79)	(0.11)	(0.89)			
rs1143634	A/G	Schizophrenia	227	1	17	209	19	435	0.46[a]	0.84	0.32
				(0.00)	(0.07)	(0.92)	(0.04)	(0.96)			
		Controls	738	1	63	674	65	1411			1.00
				(0.00)	(0.09)	(0.91)	(0.04)	(0.96)			
rs1143633	C/T	Schizophrenia	225	52	104	69	208	242	0.013	**0.0073**	0.29
				(0.23)	(0.46)	(0.31)	(0.46)	(0.54)			
		Controls	740	111	357	272	579	901			0.76
				(0.15)	(0.48)	(0.37)	(0.39)	(0.61)			
rs1143630	T/G	Schizophrenia	225	6	59	160	71	379	0.97	0.83	0.80
				(0.03)	(0.26)	(0.71)	(0.16)	(0.84)			
		Controls	736	18	190	528	226	1246			0.89
				(0.02)	(0.26)	(0.72)	(0.15)	(0.85)			
rs16944	A/G	Schizophrenia	226	57	110	59	224	228	0.11	0.032	0.69
				(0.25)	(0.49)	(0.26)	(0.50)	(0.50)			
		Controls	726	144	348	234	636	816			0.50
				(0.20)	(0.48)	(0.32)	(0.44)	(0.56)			

(a) Calculated using Fisher's exact test.
SNP: single nucleotide polymorphism; HWE: Hardy-Weinberg Disequilibrium
Numbers in parentheses represent the frequencies of genotypes and alleles. Significant P-values (< 0.013) are shown in boldface.

Figure 1 Haplotype block structure of the *IL-1β* gene. Genomic organization and linkage disequilibrium (LD) structure of the *IL-1β* gene are shown. Exons are shown as boxes. Shades of red represent extent of LD (darker red denotes D' = 1). Numbers in squares give r^2 values multiplied by 100.

schizophrenia susceptibility in Asian populations, which is consistent with the previous Asian findings [21-23]. However, there was a trend of association of rs16944, in

the opposite direction to that of the Caucasians, with schizophrenia susceptibility in female subjects. Therefore, there remains a possibility that a larger study would yield a significant difference between Japanese female schizophrenic patients and controls in the allele frequency of rs16944.

A number of genome-wide association studies (GWAS) have searched for polymorphisms associated with schizophrenia [38-43]. Although no evidence of association with *IL-1β* gene has been reported, common risk alleles in the major histocompatibility region on chromosome 6, which is involved in the immune response, have shown statistically significant evidence of association [38-40]. Furthermore, a genome-wide pharmacogenomic study has shown that *IL-1α* rs11677416, which is in weak LD with rs1143633 (r^2 = 0.094, D' = 0.809 based on HapMap Japanese and Han Chinese population data, release 22), was associated with response of neurocognitive symptoms to antipsychotic treatment [44]. These findings, together with ours, suggest genetic influence on immune alterations in schizophrenia.

A shift towards the T helper type 2 (Th2) system has been indicated in schizophrenia [45-47]. IL-1β stimulates

Table 4 Haplotype analysis of *IL-1β* gene polymorphisms

Block	Haplotype	Diagnosis	Males					Females				
			Carrier	Non-carrier	χ2	Nominal P value	Permutation P value	Carrier	Non-carrier	χ2	Nominal P value	Permutation P value
	GT	Schizophrenia	336.3	265.7	0.557	0.456	0.957	251.0	213.0	6.240	0.0125	0.118
			(0.559)	(0.441)				(0.541)	(0.459)			
		Controls	447.9	326.1				901.0	585.0			
			(0.579)	(0.421)				(0.606)	(0.394)			
1	GC	Schizophrenia	183.1	418.9	0.216	0.642	0.995	149.0	315.0	2.298	0.130	0.691
			(0.304)	(0.696)				(0.321)	(0.679)			
		Controls	226.4	547.6				422.5	1063.5			
			(0.293)	(0.707)				(0.284)	(0.716)			
	AC	Schizophrenia	82.6	519.4	0.215	0.643	0.995	63.7	400.3	3.281	0.0701	0.461
			(0.137)	(0.863)				(0.137)	(0.863)			
		Controls	99.6	674.4				158.5	1327.5			
			(0.129)	(0.871)				(0.107)	(0.893)			
	GG	Schizophrenia	321.4	280.6	0.154	0.694	0.996	231.2	228.8	5.012	0.0252	0.207
			(0.534)	(0.466)				(0.503)	(0.497)			
		Controls	422.6	353.4				837.4	652.6			
			(0.545)	(0.455)				(0.562)	(0.438)			
2	GA	Schizophrenia	183.5	418.5	0.040	0.841	1.00	156.4	303.6	5.326	0.0210	0.178
			(0.305)	(0.695)				(0.340)	(0.660)			
		Controls	232.7	543.3				422.8	1067.2			
			(0.300)	(0.700)				(0.284)	(0.716)			
	TA	Schizophrenia	97.1	504.9	0.081	0.776	0.999	72.4	387.6	0.027	0.869	1.00
			(0.161)	(0.839)				(0.157)	(0.843)			
		Controls	120.7	655.3				229.8	1260.2			
			(0.156)	(0.844)				(0.154)	(0.846)			

Numbers in parentheses represent the frequencies of haplotypes. Permutation P values were based on 10,000 permutations.

the production of prostaglandin E2, which is an important cofactor for the induction of T-helper lymphocyte activity towards Th2 direction. Significant increase in circulating mRNA expression levels of IL-1β has been observed in schizophrenic patients [9]. The changes in mRNA levels may reflect the genetic variation in *IL-1β* gene. The findings on biological roles of *IL-1β* polymorphisms, however, have not been consistent across studies. A/A genotype of rs16944 has been associated with higher gastric mucosa IL-1β levels in H. pylori positive population [48]. On the other hand, subjects with G/G genotype showed an increased release of IL-1β from mononuclear cells after stimulation with lipopolysaccharide [49]. Recent studies suggest that the functional role of rs16944 may depend on the *IL-1β* promoter region haplotypes including rs16944 and rs1143627 [50-53]. Although the findings are inconsistent, these previous studies suggest that rs16944 could affect the expression levels of IL-1β. On the other hand, the influence of rs1143633 on IL-1β expression levels has not been previously reported.

Intriguingly, rs1143633 and rs16944 have also been associated with cortisol response to dexamethasone in healthy subjects [30]. Alleles associated with increased cortisol response to dexamethasone were shown to be associated with schizophrenia in the present study. Higher rates of non-suppression to dexamethasone compared to healthy subjects have been reported in schizophrenia [54] and schizotypy [55]. On the other hand, Ismail et al [56] reported that less than 2% of their schizophrenic patients were non-suppressors. Although the findings are inconsistent, these studies indicate that schizophrenia may be associated with alteration in hypothalamic- pituitary- adrenal (HPA) axis. Taken together, our findings suggest that *IL-1β* gene polymorphisms may play a role in the HPA axis alteration in schizophrenic patients.

Our results showed significant association of rs1143633 with schizophrenia in only females. Although our male sample was not large enough to detect a small relative risk, our data suggest that susceptibility to schizophrenia is more influenced by the *IL-1β* gene variation in females. To our knowledge, no previous studies have examined the gender differences in the association between *IL-1β* gene polymorphisms and schizophrenia. However, gender differences have been reported in the association between schizophrenia and RELA gene [27] encoding the major component of NF-κB, which is activated by IL-1β. Taken together with our results, the influence of IL-1β on susceptibility to schizophrenia may differ between genders. Indeed, gender differences in immunity have been reported in previous studies [36]. IL-1 release from mononucleated cells has been shown to be menstrual phase dependent in females and lower in males [57].

Furthermore, in vitro stimulation of lymphocytes with phytohemagglutinin has shown that females produce more Th2 cytokines than males [58]. Thus, future studies investigating associations of immune-related genes with schizophrenia should take into consideration the possible gender differences.

There are some limitations to this study. The ethnicity of the participants was based on self-reports and was not confirmed by genetic analyses. Our positive results might be derived from sample bias due to population stratification, although the Japanese are a relatively homogeneous population. Furthermore, structured interview such as SCID (Structured Clinical Interview for DSM) was not used for diagnosis in this study. Finally, the function of the *IL-1β* gene SNPs are unclear. Future studies are necessary to elucidate the function and its relationship with the pathogenesis of schizophrenia.

Conclusions

Our results suggest that rs1143633 of *IL-1β* gene is associated with schizophrenia susceptibility in a Japanese population and that the influence of *IL-1β* gene variations on susceptibility to schizophrenia may be greater in females than in males. We obtained no significant evidence for a well-studied polymorphism rs16944 being associated with schizophrenia, which is consistent with previous studies in Asian populations. However, a trend of higher A allele frequency of rs16944 in female patients with schizophrenia leaves open a possibility that a larger study may yield a significant difference. The results of the present study provide further support for the role of IL-1β in the etiology of schizophrenia. Future studies are warranted to replicate the present findings and to reveal the functional role of *IL-1β* gene in pathophysiology of schizophrenia.

Author details
[1]Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo, 187-8502, Japan. [2]Department of Psychiatry, Shinshu University School of Medicine, Matsumoto, 390-8621, Japan. [3]Core Research of Evolutional Science & Technology (CREST), Japan Science and Technology Agency (JST), Tokyo, 102-0075, Japan. [4]Department of Medical Genetics, Majors of Medical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, 305-8577, Japan. [5]Yokohama Shinryo Clinic, Yokohama, 221-0835, Japan. [6]National Center of Neurology and Psychiatry, Kodaira, Tokyo, 187-8502, Japan.

Authors' contributions

DS and HK designed the study and DS wrote the draft of the manuscript. DS, HH, TT, KH, MO, MT, and HK made the diagnosis according to DSM-IV criteria. DS, HH, TT, KH, MO, and HK screened the healthy participants using the Mini International Neuropsychiatric Interview (M.I.N.I.). DS and YI performed the genotyping. HK supervised the data analysis and writing of the paper. TH and NA also supervised the writing of the paper and gave critical comments on the manuscript. All authors contributed to and have approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

References

1. Baker I, Masserano J, Wyatt RJ: Serum cytokine concentrations in patients with schizophrenia. *Schizophr Res* 1996, 20:199-203.
2. Barak V, Barak Y, Levine J, Nisman B, Roisman I: Changes in interleukin-1 beta and soluble interleukin-2 receptor levels in CSF and serum of schizophrenic patients. *J Basic Clin Physiol Pharmacol* 1995, 6:61-69.
3. Katila H, Hurme M, Wahlbeck K, Appelberg B, Rimon R: Plasma and cerebrospinal fluid interleukin-1 beta and interleukin-6 in hospitalized schizophrenic patients. *Neuropsychobiology* 1994, 30:20-23.
4. Kim YK, Kim L, Lee MS: Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics. *Schizophr Res* 2000, 44:165-175.
5. Kim YK, Lee MS, Suh KY: Decreased interleukin-2 production in Korean schizophrenic patients. *Biol Psychiatry* 1998, 43:701-704.
6. Xu HM, Wei J, Hemmings GP: Changes of plasma concentrations of interleukin-1 alpha and interleukin-6 with neuroleptic treatment for schizophrenia. *Br J Psychiatry* 1994, 164:251-253.
7. Soderlund J, Schroder J, Nordin C, Samuelsson M, Walther-Jallow L, Karlsson H, Erhardt S, Engberg G: Activation of brain interleukin-1beta in schizophrenia. *Mol Psychiatry* 2009, 14:1069-1071.
8. Kowalski J, Blada P, Kucia K, Madej A, Herman ZS: Neuroleptics normalize increased release of interleukin- 1 beta and tumor necrosis factor-alpha from monocytes in schizophrenia. *Schizophr Res* 2001, 50:169-175.
9. Liu L, Jia F, Yuan G, Chen Z, Yao J, Li H, Fang C: Tyrosine hydroxylase, interleukin-1beta and tumor necrosis factor-alpha are overexpressed in peripheral blood mononuclear cells from schizophrenia patients as determined by semi-quantitative analysis. *Psychiatry Res* 2010, 176:1-7.
10. Gilmore JH, Fredrik Jarskog L, Vadlamudi S, Lauder JM: Prenatal infection and risk for schizophrenia: IL-1beta, IL-6, and TNFalpha inhibit cortical neuron dendrite development. *Neuropsychopharmacology* 2004, 29:1221-1229.
11. Marx CE, Jarskog LF, Lauder JM, Lieberman JA, Gilmore JH: Cytokine effects on cortical neuron MAP-2 immunoreactivity: implications for schizophrenia. *Biol Psychiatry* 2001, 50:743-749.
12. Levinson DF, Mahtani MM, Nancarrow DJ, Brown DM, Kruglyak L, Kirby A, Hayward NK, Crowe RR, Andreasen NC, Black DW, *et al*: Genome scan of schizophrenia. *Am J Psychiatry* 1998, 155:741-750.
13. DeLisi LE, Shaw SH, Crow TJ, Shields G, Smith AB, Larach VW, Wellman N, Loftus J, Nanthakumar B, Razi K, *et al*: A genome-wide scan for linkage to chromosomal regions in 382 sibling pairs with schizophrenia or schizoaffective disorder. *Am J Psychiatry* 2002, 159:803-812.
14. Lewis CM, Levinson DF, Wise LH, DeLisi LE, Straub RE, Hovatta I, Williams NM, Schwab SG, Pulver AE, Faraone SV, *et al*: Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia. *Am J Hum Genet* 2003, 73:34-48.
15. Faraone SV, Hwu HG, Liu CM, Chen WJ, Tsuang MM, Liu SK, Shieh MH, Hwang TJ, Ou-Yang WC, Chen CY, *et al*: Genome scan of Han Chinese schizophrenia families from Taiwan: confirmation of linkage to 10q22.3. *Am J Psychiatry* 2006, 163:1760-1766.
16. Hanninen K, Katila H, Saarela M, Rontu R, Mattila KM, Fan M, Hurme M, Lehtimaki T: Interleukin-1 beta gene polymorphism and its interactions with neuregulin-1 gene polymorphism are associated with schizophrenia. *Eur Arch Psychiatry Clin Neurosci* 2008, 258:10-15.
17. Papiol S, Rosa A, Gutierrez B, Martin B, Salgado P, Catalan R, Arias B, Fananas L: Interleukin-1 cluster is associated with genetic risk for schizophrenia and bipolar disorder. *J Med Genet* 2004, 41:219-223.
18. Zanardini R, Bocchio-Chiavetto L, Scassellati C, Bonvicini C, Tura GB, Rossi G, Perez J, Gennarelli M: Association between IL-1beta -511C/T and IL-1RA (86bp)n repeats polymorphisms and schizophrenia. *J Psychiatr Res* 2003, 37:457-462.
19. Shirts BH, Wood J, Yolken RH, Nimgaonkar VL: Association study of IL10, IL1beta, and IL1RN and schizophrenia using tag SNPs from a comprehensive database: suggestive association with rs16944 at IL1beta. *Schizophr Res* 2006, 88:235-244.
20. Betcheva ET, Mushiroda T, Takahashi A, Kubo M, Karachanak SK, Zaharieva IT, Vazharova RV, Dimova II, Milanova VK, Tolev T, *et al*: Case-control association study of 59 candidate genes reveals the DRD2 SNP rs6277 (C957T) as the only susceptibility factor for schizophrenia in the Bulgarian population. *J Hum Genet* 2009, 54:98-107.
21. Chowdari KV, Xu K, Zhang F, Ma C, Li T, Xie BY, Wood J, Trucco M, Tsoi WF, Saha N, *et al*: Immune related genetic polymorphisms and schizophrenia among the Chinese. *Hum Immunol* 2001, 62:714-724.
22. Tatsumi M, Sasaki T, Sakai T, Kamijima K, Fukuda R, Kunugi H, Hattori M, Nanko S: Genes for interleukin-2 receptor beta chain, interleukin-1 beta, and schizophrenia: no evidence for the association or linkage. *Am J Med Genet* 1997, 74:338-341.
23. Watanabe Y, Nunokawa A, Kaneko N, Muratake T, Koizumi M, Someya T: Lack of association between the interleukin-1 gene complex and schizophrenia in a Japanese population. *Psychiatry Clin Neurosci* 2007, 61:364-369.
24. American Psychiatric Association: *DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. 4 edition.* Washington D.C.: American Psychiatric Press; 1994.
25. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC: The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *J Clin Psychiatry* 1998, 59(Suppl 20):22-33, quiz 34-57.
26. Otsubo T, Tanaka K, Koda R, Shinoda J, Sano N, Tanaka S, Aoyama H, Mimura M, Kamijima K: Reliability and validity of Japanese version of the Mini-International Neuropsychiatric Interview. *Psychiatry Clin Neurosci* 2005, 59:517-526.
27. Hashimoto R, Ohi K, Yasuda Y, Fukumoto M, Yamamori H, Takahashi H, Iwase M, Okochi T, Kazui H, Saitoh O, *et al*: Variants of the RELA gene are associated with schizophrenia and their startle responses. *Neuropsychopharmacology* 2011, 36:1921-1931.
28. Richards M, Iijima Y, Kondo H, Shizuno T, Hori H, Arima K, Saitoh O, Kunugi H: Association study of the vesicular monoamine transporter 1 (VMAT1) gene with schizophrenia in a Japanese population. *Behav Brain Funct* 2006, 2:39.
29. Sasayama D, Hori H, Teraishi T, Hattori K, Ota M, Matsuo J, Kawamoto Y, Kinoshita Y, Higuchi T, Amano N, Kunugi H: Association of interleukin-1beta genetic polymorphisms with cognitive performance in elderly females without dementia. *J Hum Genet* .
30. Sasayama D, Hori H, Iijima Y, Teraishi T, Hattori K, Ota M, Fujii T, Higuchi T, Amano N, Kunugi H: Modulation of cortisol responses to the DEX/CRH test by polymorphisms of the interleukin-1beta gene in healthy adults. *Behav Brain Funct* 2011, 7:23.
31. Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. *Bioinformatics* 2005, 21:263-265.
32. Wigginton JE, Cutler DJ, Abecasis GR: A note on exact tests of Hardy-Weinberg equilibrium. *Am J Hum Genet* 2005, 76:887-893.
33. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC: PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* 2007, 81:559-575.
34. Li J, Ji L: Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. *Heredity* 2005, 95:221-227.
35. Nyholt DR: A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. *Am J Hum Genet* 2004, 74:765-769.
36. Gillum TL, Kuennen MR, Schneider S, Moseley P: A review of sex differences in immune function after aerobic exercise. *Exerc Immunol Rev* 2011, 17:104-121.
37. Xu M, He L: Convergent evidence shows a positive association of interleukin-1 gene complex locus with susceptibility to schizophrenia in the Caucasian population. *Schizophr Res* 2010, 120:131-142.

38. Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, Werge T, Pietilainen OP, Mors O, Mortensen PB, *et al*: Common variants conferring risk of schizophrenia. *Nature* 2009, 460:744-747.
39. Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, Sullivan PF, Sklar P: Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. *Nature* 2009, 460:748-752.
40. Shi J, Levinson DF, Duan J, Sanders AR, Zheng Y, Pe'er I, Dudbridge F, Holmans PA, Whittemore AS, Mowry BJ, *et al*: Common variants on chromosome 6p22.1 are associated with schizophrenia. *Nature* 2009, 460:753-757.
41. Ikeda M, Aleksic B, Kinoshita Y, Okochi T, Kawashima K, Kushima I, Ito Y, Nakamura Y, Kishi T, Okumura T, *et al*: Genome-wide association study of schizophrenia in a Japanese population. *Biol Psychiatry* 2011, 69:472-478.
42. Yamada K, Iwayama Y, Hattori E, Iwamoto K, Toyota T, Ohnishi T, Ohba H, Maekawa M, Kato T, Yoshikawa T: Genome-wide association study of schizophrenia in Japanese population. *PLoS One* 2011, 6:e20468.
43. Rietschel M, Mattheisen M, Degenhardt F, Kahn RS, Linszen DH, Os JV, Wiersma D, Bruggeman R, Cahn W, de Haan L, *et al*: Association between genetic variation in a region on chromosome 11 and schizophrenia in large samples from Europe. *Mol Psychiatry* .
44. McClay JL, Adkins DE, Aberg K, Bukszar J, Khachane AN, Keefe RS, Perkins DO, McEvoy JP, Stroup TS, Vann RE, *et al*: Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. *Neuropsychopharmacology* 2010, 36:616-626.
45. Schwarz MJ, Chiang S, Muller N, Ackenheil M: T-helper-1 and T-helper-2 responses in psychiatric disorders. *Brain Behav Immun* 2001, 15:340-370.
46. Schwarz MJ, Muller N, Riedel M, Ackenheil M: The Th2-hypothesis of schizophrenia: a strategy to identify a subgroup of schizophrenia caused by immune mechanisms. *Med Hypotheses* 2001, 56:483-486.
47. Muller N, Riedel M, Gruber R, Ackenheil M, Schwarz MJ: The immune system and schizophrenia. An integrative view. *Ann N Y Acad Sci* 2000, 917:456-467.
48. Hwang IR, Kodama T, Kikuchi S, Sakai K, Peterson LE, Graham DY, Yamaoka Y: Effect of interleukin 1 polymorphisms on gastric mucosal interleukin 1beta production in Helicobacter pylori infection. *Gastroenterology* 2002, 123:1793-1803.
49. Iacoviello L, Di Castelnuovo A, Gattone M, Pezzini A, Assanelli D, Lorenzet R, Del Zotto E, Colombo M, Napoleone E, Amore C, *et al*: Polymorphisms of the interleukin-1beta gene affect the risk of myocardial infarction and ischemic stroke at young age and the response of mononuclear cells to stimulation in vitro. *Arterioscler Thromb Vasc Biol* 2005, 25:222-227.
50. Chen H, Wilkins LM, Aziz N, Cannings C, Wyllie DH, Bingle C, Rogus J, Beck JD, Offenbacher S, Cork MJ, *et al*: Single nucleotide polymorphisms in the human interleukin-1B gene affect transcription according to haplotype context. *Hum Mol Genet* 2006, 15:519-529.
51. Wen AQ, Wang J, Feng K, Zhu PF, Wang ZG, Jiang JX: Effects of haplotypes in the interleukin 1beta promoter on lipopolysaccharide-induced interleukin 1beta expression. *Shock* 2006, 26:25-30.
52. Wen AQ, Gu W, Wang J, Feng K, Qin L, Ying C, Zhu PF, Wang ZG, Jiang JX: Clinical relevance of interleukin-1beta promoter polymorphisms (-1470, -511 and -31) in patients with major trauma. *Shock* 2009.
53. Hall SK, Perregaux DG, Gabel CA, Woodworth T, Durham LK, Huizinga TW, Breedveld FC, Seymour AB: Correlation of polymorphic variation in the promoter region of the interleukin-1 beta gene with secretion of interleukin-1 beta protein. *Arthritis Rheum* 2004, 50:1976-1983.
54. Sharma RP, Pandey GN, Janicak PG, Peterson J, Comaty JE, Davis JM: The effect of diagnosis and age on the DST: a metaanalytic approach. *Biol Psychiatry* 1988, 24:555-568.
55. Hori H, Teraishi T, Ozeki Y, Hattori K, Sasayama D, Matsuo J, Kawamoto Y, Kinoshita Y, Higuchi T, Kunugi H: Schizotypal Personality in Healthy Adults Is Related to Blunted Cortisol Responses to the Combined Dexamethasone/Corticotropin-Releasing Hormone Test. *Neuropsychobiology* 2011, 63:232-241.
56. Ismail K, Murray RM, Wheeler MJ, O'Keane V: The dexamethasone suppression test in schizophrenia. *Psychol Med* 1998, 28:311-317.
57. Lynch EA, Dinarello CA, Cannon JG: Gender differences in IL-1 alpha, IL-1 beta, and IL-1 receptor antagonist secretion from mononuclear cells and urinary excretion. *J Immunol* 1994, 153:300-306.
58. Giron-Gonzalez JA, Moral FJ, Elvira J, Garcia-Gil D, Guerrero F, Gavilan I, Escobar L: Consistent production of a higher TH1:TH2 cytokine ratio by stimulated T cells in men compared with women. *Eur J Endocrinol* 2000, 143:31-36.

Phencyclidine-Induced Decrease of Synaptic Connectivity via Inhibition of BDNF Secretion in Cultured Cortical Neurons

Naoki Adachi[1,2], Tadahiro Numakawa[1,2], Emi Kumamaru[1,2], Chiaki Itami[3], Shuichi Chiba[1], Yoshimi Iijima[1], Misty Richards[1,4], Ritsuko Katoh-Semba[5] and Hiroshi Kunugi[1,2]

[1]Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo 187-8502, Japan, [2]Core Research for Evolutional Science and Technology Program (CREST), Japan Science and Technology Agency (JST), Saitama 332-0012, Japan, [3]Department of Physiology, Faculty of Medicine, Saitama Medical University, Saitama, 350-0495, Japan, [4]Center of Neuropharmacology and Neuroscience, Albany Medical College, Albany, NY 12208, USA and [5]Laboratory for Molecular Neurogenesis, RIKEN Brain Science Institute, Saitama 351-0198, Japan

Address correspondence to Dr Tadahiro Numakawa, 4-1-1 Ogawa-Higashi, Kodaira, Tokyo 187-8502, Japan. Email: numakawa@ncnp.go.jp.

Repeated administration of phencyclidine (PCP), a noncompetitive N-methyl-D-aspartate (NMDA) receptor blocker, produces schizophrenia-like behaviors in humans and rodents. Although impairment of synaptic function has been implicated in the effect of PCP, the molecular mechanisms have not yet been elucidated. Considering that brain-derived neurotrophic factor (BDNF) plays an important role in synaptic plasticity, we examined whether exposure to PCP leads to impaired BDNF function in cultured cortical neurons. We found that PCP caused a transient increase in the level of intracellular BDNF within 3 h. Despite the increased intracellular amount of BDNF, activation of Trk receptors and downstream signaling cascades, including MAPK/ERK1/2 and PI3K/Akt pathways, were decreased. The number of synaptic sites and expression of synaptic proteins were decreased 48 h after PCP application without any impact on cell viability. Both electrophysiological and biochemical analyses revealed that PCP diminished glutamatergic neurotransmission. Furthermore, we found that the secretion of BDNF from cortical neurons was suppressed by PCP. We also confirmed that PCP-caused down-regulation of Trk signalings and synaptic proteins were restored by exogenous BDNF application. It is possible that impaired secretion of BDNF and subsequent decreases in Trk signaling are responsible for the loss of synaptic connections caused by PCP.

Keywords: neurotrophin, NMDA receptors, schizophrenia, synaptic function, TrkB signaling pathways

Introduction

Phencyclidine (PCP), a noncompetitive and use-dependent blocker of the N-methyl-D-aspartate (NMDA)-type glutamate receptors, induces psychotic symptoms that are similar to schizophrenia in humans (Allen and Young 1978; Javitt and Zukin 1991). Unlike other psychotomimetic drugs, such as amphetamine, PCP induces negative symptoms (e.g., flattening of affect, alogia, anhedonia, and social withdrawal) and cognitive deficits in addition to positive symptoms (e.g., delusions, hallucinations, and formal thought disorder) of schizophrenia (Andreasen 1995; Olney and Farber 1995; Jentsch and Roth 1999). In rodents, PCP causes schizophrenia-related behaviors, such as disruption in prepulse inhibition (Mansbach and Geyer 1989), stereotyped behavior, and social isolation (Sams-Dodd 1996), increased immobility in forced swimming (Noda et al. 1995), and impaired learning and memory in various maze tasks (Kesner et al. 1983; Handelmann

et al. 1987; Danysz et al. 1988; Wass et al. 2006). Extensive reduction in the number of spines in the rat prefrontal cortex has been demonstrated with subchronic PCP treatment (Hajszan et al. 2006), indicating a substantial contribution of abnormal synaptic function to the development of schizophrenia-related behaviors (Mirnics et al. 2001; Frankle et al. 2003; McCullumsmith et al. 2004). Moreover, recent findings suggest that altered expression of genes encoding synapse-associated proteins also play a critical role in the development of schizophrenia (Harrison and Weinberger 2005). Human postmortem studies show reduced dendritic spine density of pyramidal cells in the prefrontal cortex of subjects with schizophrenia (Glantz and Lewis 1997, 2000; Knable et al. 2004). However, the molecular mechanisms underlying the effect of PCP on reduced synaptic connection have not yet been elucidated.

BDNF, a member of the neurotrophin family, plays an important role in synaptic plasticity (Stoop and Poo 1996; Lu 2003; Arancio and Chao 2007, Numakawa et al. 2011) through activation of its receptor Tropomyosin-related kinase B (TrkB) and consequent stimulation of downstream signaling pathways, including mitogen-activated protein/extracellular signal-regulated kinase (MAPK/ERK), phosphoinositide 3-kinase/Akt (PI3K/Akt), and phospholipase C-γ (PLC-γ). We have recently reported important regulatory roles of BDNF in synaptic functions of cortical neurons (Kumamaru et al. 2011). BDNF shows broad expression in the developing and adult mammalian brain (especially, the hippocampus, cerebral cortex, cerebellum, and amygdala) (Ernfors et al. 1990; Hofer et al. 1990; Yan et al. 1997; Conner et al. 1997). As expected, impairment of BDNF/TrkB function has been implicated in the pathogenesis of schizophrenia (Durany and Thome 2004; Angelucci et al. 2005; Lewis et al. 2005), as well as other neuropsychiatric diseases, such as depression (Altar 1999), drug addiction (Davis 2008), Huntington's disease (Zuccato et al. 2001; Gauthier et al. 2004), and Rett syndrome (Chen et al. 2003; Nelson et al. 2008). We found that disrupted-in-schizophrenia 1 (DISC1) and dysbindin, both of which confer susceptibility to schizophrenia, are involved in the regulation of ERK1/2 or Akt signaling (Numakawa et al. 2004; Hashimoto et al. 2006). We have also revealed that glucocorticoid, a stress hormone closely linked to depression (e.g., Kunugi et al. 2006), hampers the synaptic function of BDNF in cortical neurons (Numakawa et al. 2009).

Since expression and secretion of BDNF are facilitated by neuronal activity (Lessmann et al. 2003; Kuczewski et al. 2009),

it is likely that PCP may decrease the expression and/or secretion of BDNF via blockade of neuronal activity. Importantly, increased expression of BDNF was reported in rat hippocampal tissue after acute (Kalinichev et al. 2008) and chronic (Takahashi et al. 2006; Harte et al. 2007) treatment with PCP, although one study reported conflicting results (Semba et al. 2006). In the present study, we investigated changes in expression and secretion of BDNF, activity of downstream signaling cascades stimulated via Trk receptors and synaptic function after PCP exposure.

Materials and Methods

Cortical Cultures and PCP Treatment
Cortical cultures were prepared from postnatal day 1 or 2 old rats (Wistar, SLC, Shizuoka, Japan) as described previously (Numakawa et al. 2002). Dissociated cells were plated at a final density of $5 \times 10^5/cm^2$ on polyethyleneimine-coated culture dishes for immunoprecipitation, immunoblotting, and amino acid measurement. For Ca^{2+} imaging, cortical neurons were cultured on polyethylenimine-coated cover glasses (Matsunami, Osaka, Japan) with FlexiPERM (Greiner Bio-One GmbH, Germany). For immunostaining or electrophysiological recording, neurons were plated on glass-bottom dishes (Matsunami) with a glial feeder layer. The culture medium (5/5 DF) contained 5% fetal bovine serum, 5% heated-inactivated horse serum, 90% of a 1:1 mixture of Dulbecco's modified Eagle's medium, and Ham's F-12 medium. PCP (Sigma-Aldrich, MO) was added to the neurons by bath application at 10–11 days in vitro (DIVs), followed by incubation of the cultures for 3, 6, or 48 h in the presence of PCP before immunocytochemistry, immunoprecipitation, immunoblotting, amino acid measurement and electrophysiological recording. Pure astroglial cultures were prepared as described previously (Hatanaka et al. 1988). Astroglial cells were obtained from cerebral cortex of postnatal day 1 or 2 old rats. All animals were treated according to the institutional guidelines for the care and use of animals.

Immunoblotting
Cells were lysed in sodium dodecyl sulfate (SDS) lysis buffer containing 1% SDS, 20 mM Tris-HCl (pH 7.4), 5 mM ethylene-diamine-tetraacetic acid (EDTA) (pH 8.0), 10 mM NaF, 2 mM Na_3VO_4, 0.5 mM phenylarsine oxide, and 1 mM phenylmethylsulfonyl fluoride. The protein concentration was quantified using a BCA Protein Assay Kit (Pierce Biotechnology Inc., IL), and equivalent amounts of total protein were assayed for each immunoblotting. Primary antibodies were used at the following dilutions: anti-BDNF (1:500, Santa Cruz Biotechnology Inc., CA), anti-TrkB (1:1000, BD Biosciences, NJ), anti-Trk (1:1000, Santa Cruz Biotechnology Inc.), anti-pTyr (1:1000, Upstate, VA), anti-Akt (1:1000, Cell Signaling, MA), anti-pAkt (1:1000, Cell Signaling), anti-ERK (1:1000, Cell Signaling), anti-pERK (1:1000, Cell Signaling), anti-synaptotagmin (1:1000, Calbiochem, Darmstadt, Germany), anti-GluR1 (1:500, Sigma), anti-NR2B (1:500, Sigma), anti-SNAP25 (1:1000, Synaptic Systems, Goettingen, Germany), anti-Bcl-2 (1:1000, BD Biosciences), anti-Bad (1:1000, BD Biosciences), anti-TUJ1 (1:5000, Berkeley Antibody Company, CA), and βactin (1:5000, Sigma) antibodies. The immunoreactivity was quantified by using Lane and Spot Analyzer software (ATTO Corporation, Tokyo, Japan). At least 3 independent series of cultures were used for each set of experiments.

Immunoprecipitation
To detect the phosphorylation of Trk receptors, immunoprecipitation was carried out (Numakawa et al. 2002; Numakawa et al. 2009). After cells were lysed with 1% Triton-X buffer (20 mM Tris-HCl (pH 7.4), 5 mM EDTA, 150 mM NaCl, 1% Triton-X100), anti-Trk antibody (Santa Cruz Biotechnology Inc.) prebound Protein G-Sepharose beads (Amersham Pharmacia, NJ) were mixed with the lysates containing 300 µg of total protein and rotated for 3 h at 4 °C. After 3 washes with the lysis buffer, the proteins that bound the affinity beads were

separated by SDS-polyacryl- amide gel electrophoresis (SDS-PAGE) and analyzed for immunoblotting with anti-pTyr (1:1000, Upstate) antibody.

Detection of Cell Surface TrkB
After a gentle wash with ice-cold phosphate-buffered saline (PBS), cells were incubated with 1.1 mg/mL of EZ-Link Sulfo-N-hydroxy- succinimidobiotin (NHS-biotin)-LC-Biotin (Pierce Biotechnology Inc.) in PBS at 4 °C for 20 min. Then, excessive NHS Biotin was quenched with 0.1 M of glycine in PBS and removed by extensive wash with ice-cold PBS. The biotinylated cells were lysed in 1% Triton-X buffer (20 mM of Tris-HCl (pH 7.4), 5 mM of EDTA, 150 mM of NaCl, 1% Triton-X100). Lysates containing equal amounts of protein were mixed with 50 µL of immobilized Neutravidin beads (UltraLink Immobilized NeutrAvidin protein, Pierce Biotechnology Inc.) and incubated at 4 °C for 1 h with gentle rotation. Centrifuged beads were washed 3 times with lysis buffer. The biotin-labeled cell surface proteins were separated by SDS-PAGE and immunoblotted with anti-TrkB antibody (1:1000, BD Biosciences).

Immunocytochemistry
For immunocytochemical staining, neurons were fixed with 4% paraformaldehyde (Sigma) and 4% sucrose in Dulbecco's PBS for 20 min at room temperature. The cells were incubated with PBS containing 0.2% Triton-X (Sigma) for 5 min and blocked by 10% horse serum in PBS for 1 h at 37 °C. Then, anti-MAP2 monoclonal antibody (isotype: IgG1, 1:250, Sigma), anti-BDNF polyclonal antibody (2 µg/µL, produced by Dr Ritsuko Katoh-Semba: Katoh-Semba et al. 1997), anti-GAD67 (glutamic acid decarboxylase 67 kD) monoclonal antibody (1:2000, Millipore, CA) and anti-synaptotagmin monoclonal antibody (isotype IgG2a, 1:100, Chemicon, CA) were applied overnight at 4 °C. BDNF and synaptotagmin were visualized by isotype-specific secondary antibody conjugated with Alexa 488 (1:200, Molecular Probes, CA). MAP2 was visualized by anti-mouse secondary antibody conjugated with Alexa 546 (1:2000, Molecular Probe). A fluorescent microscope (Axiovert 200, Carl Zeiss, Oberkochen, Germany) was used to obtain images. When quantification of BDNF immunoreactivity was conducted, we measured mean intensity of randomly selected areas of cell body or primary dendrites by using imaging software Slide Book TM 3.0 (Intelligent Imaging Innovations Inc., CO).

MTT Assay
To calculate cell viability, the metabolic activity of mitochondria was estimated by measuring the mitochondrial-dependent conversion of the tetrazolium salt, MTT (Sigma) (Numakawa et al. 2009). In brief, after treatment of PCP for 48 h, cultured cells were incubated with MTT solution. Two hours later, cultures were lysed and the metabolic activity of the mitochondrial reductase was estimated.

Detection of BDNF Secretion
Following washes with neurobasal medium and 0.1 mg/mL BSA, cultured neurons were incubated with or without PCP (1 µM) in neurobasal medium containing anti-BDNF antibody (2 µg/mL, Santa Cruz Biotechnology Inc.) for 6 h. Then, medium was carefully collected and the secreted BDNF captured by the antibody was immunoprecipitated. After 3 washes with the lysis buffer, BDNF in immunoprecipitates was detected by immunoblotting with the same anti-BDNF antibody (Santa Cruz Biotechnology Inc.) or ELISA assay (BDNF-ELISA E-max; Promega, WI) with another anti-BDNF antibody, a component of the ELISA kit. For detection of BDNF secretion from cortical acute slices, 200-µm-thick coronal sections were prepared using a microtome (VT1000S, Leica, Nussloch, Germany) from prefrontal cortex of postnatal 30–40 days old male rats in ice-cold HEPES-buffered solution (containing 120 mM NaCl, 4 mM KCl, 1.2 mM KH_2PO_4, 1 mM $MgSO_4$, 2 mM $CaCl_2$, 30 mM glucose, and 20 mM HEPES, pH 7.4). Each slice, which was obtained from right and left cortical hemisphere, was assigned to control and PCP treatment. Freely floating slice sections were incubated with HEPES-buffered solution at 37 °C for 4 h before sampling. Then, after washing several times, secreted BDNF was determined in a similar way used in the culture experiments.

Detection of Amino Acid Neurotransmitters

The amount of amino acid released from cultured neurons was measured as described previously (Numakawa et al. 2002). Briefly, high-performance liquid chromatography (HPLC; Shimazu Co., Kyoto, Japan) was used to measure the amino acids released into the modified HEPES-buffered Krebs Ringer solution (KRH; containing 130 mM NaCl, 5 mM KCl, 1.2 mM NaH$_2$PO$_4$, 1.8 mM CaCl$_2$, 10 mM glucose, 1% bovine serum albumin, and 25 mM HEPES, pH 7.4). After the cultures were washed 3 times with KRH buffer, fresh KRH buffer was added to the cultures and collected without stimulation (1 min) as the basal release. Then, potassium (50 mM KCl for 1 min) was added to the cultures in order to induce depolarization.

Electrophysiology

Whole-cell voltage clamp recordings were performed on cultured cortical neurons using an AxoClamp 2B amplifier (Molecular Devices). Cells were continuously superfused with external solution containing 150 mM NaCl, 4 mM KCl, 2 mM CaCl, 1 mM MgCl$_2$, 10 mM HEPES, 10 mM D-glucose, 10 μM glycine (pH = 7.4, 310 mOsm). Miniature excitatory postsynaptic currents (mEPSCs) were isolated by adding picrotoxin (100 μM) and tetrodotoxin (0.5 μM) to the bath. Recordings were performed for 5 min, which enabled us to collect more than 1000 events. Patch electrodes (7-12 MΩ) contained 130 mM Cs-methane sulfonate, 10 mM CsCl, 10 mM MgCl$_2$, 10 mM HEPES, 5 mM MgATP, and 1 mM Na$_2$GTP (pH 7.3, 300 mOsm). All experiments were carried out at room temperature (27 °C). Cells with an input resistance >200 MΩ (range: 300-800 MΩ) were used. Each neuron was voltage-clamped at -70 mV. For each recording, series resistance and input resistance were continuously monitored, and if these values changed by >15%, the data were discarded. Signals were filtered at 3 kHz and digitized at 10 kHz (Digidata 1320A: Molecular Devices). Off-line analysis of mEPSCs was carried out using Clampfit v 9.2 (Molecular Devices). Miniature events were detected using Mini Analysis software (Synaptosoft) with an amplitude threshold of -5 pA. The events were further inspected visually to exclude inappropriate data, such as overlapped events or events with a noisy baseline.

Imaging of Intracellular Ca^{2+}

Ca^{2+} imaging was performed using fluo-3 dye (Molecular Probes) as previously reported (Numakawa et al. 2002). The changes in the fluo-3 intensity through the fluorescent microscope were analyzed and quantified using Slide Book TM 3.0 (Intelligent Imaging Innovations Inc.) from randomly selected cell bodies. Ca^{2+} imaging experiments were performed at least 3 times for each experimental condition.

Total RNA Extraction and Reverse Transcription

Total RNA was extracted from cultured cells using the RNeasy Plus Kit (QIAGEN, CA) according to the manufacturer's manual. Cells were homogenized by QIAshredder (QIAGEN). To prevent genomic DNA contamination, gDNA Eliminator column (QIAGEN) was used. Total RNA (1 μg) was mixed with SuperScript VILO enzyme and reaction mixes (Invitrogen, CA) in a total volume of 20 μL. After incubation at 25 °C for 10 min, the mixture was heated to 42 °C for 60 min and followed by an inactivation step (85 °C, 5 min). The cDNA solutions were stored at -80 °C until used.

Quantitative PCR

For real-time PCR analyses of mRNA, cDNA was prepared from cultured cortical neurons or pure astrocytes using a TaqMan Cells-to-Ct kit (Applied Biosystems, CA) according to the manufacturer's protocol. Each cDNA was amplified with specific TaqMan Gene Expression Assays (Rn02531967_s1 for rat BDNF; Rn00565046_m1 for rat MAP2; Rn00566603_m1 for rat GFAP: glial fibrillary acidic protein). ABI prism 7000 was used for amplifications. Ct of target mRNA was obtained using Sequence Detection System software (ABI). Serial dilution (1:1, 1:3.3, 1:10, 1:33, and 1:100) of pooled samples was used as a standard. Each gene amplification was normalized with rat GAPDH control (4352338E).

Statistical Analysis

Data are expressed as mean ± standard deviation, and statistical significance was calculated using a one-way ANOVA followed by Scheffe's post hoc test in SPSS ver.18 (SPSS Japan, Tokyo, Japan) if not otherwise specified. The probability values of less than 5% were considered significant.

Results

Transient Increase of Intracellular BDNF Levels by PCP

To determine the acute effects of PCP on neurons, cortical cultures (at DIV 10 and 11) were exposed to PCP, followed by examination of BDNF and its receptor expression. Interestingly, Western blot analyses revealed that 3-h PCP treatment significantly increased levels of intracellular BDNF (14 kD, mature BDNF) (e.g., PCP 1 μM: 152 ± 21.7% of control, $P <$ 0.01) (Fig. 1A,B). BDNF expression was increased 6 h after 0.1 μM PCP application as well, though statistical significance was not reached (Fig. 1A,B). Expression of TrkB and p75 (low affinity receptor for BDNF) were not altered by 3- or 6-h PCP application (Fig. 1A, Supplementary Fig. 1A). Expression of β-actin and TUJ1 (both are controls) were also intact after PCP exposure (Fig. 1A). To check involvement of de novo synthesis in the up regulation of BDNF, we investigated BDNF mRNA after PCP stimulation. Unexpectedly, a significant reduction in BDNF mRNA expression was induced by PCP (1 μM, 3 h) (Supplementary Fig. 1B), suggesting that the PCP-induced increase in intracellular BDNF expression is not due to an increase of BDNF translation. Although the cell body size of neurons was not affected (Fig. 1C), immunostaining with anti-BDNF antibody showed that the intensity of granular signals in MAP2-positive neurons increased after PCP treatment (1 μM, 3 h) (cell body: 123 ± 10% of control, $P <$ 0.001, dendrite: 115 ± 13% of control, $P <$ 0.001, t-test) (Fig. 1D,E). Such granular signals of BDNF were observed in only non-GAD-positive neurons (Supplementary Fig. 1C), suggesting that the selected BDNF-positive neurons used to estimate immunoreactivity were glutamatergic neurons. In this study, we confirmed a very small proportion of glial cells in our cortical cultures (Supplementary Fig. 2A) and much higher expression of BDNF mRNA in the cortical cultures than that in pure astrocyte cultures. Furthermore, PCP decreased rather than increased the BDNF levels in the pure astrocytes (Supplementary Fig. 2B), indicating that the increased expression of BDNF was specific to neurons.

PCP Diminished Activity of BDNF/Trks Signaling

The effect of PCP on activation (phosphorylation) of Trk receptors and downstream signaling pathways was examined. In spite of the increased intracellular BDNF, phosphorylation of Trk receptors was suppressed by 3- and 6-h PCP treatment (PCP 1 μM, 3 h: 49.3 ± 16.3% of control; PCP 1 μM, 6 h: 56.8 ± 10.1% of control, $P <$ 0.001 and $P <$ 0.05, respectively) (Fig. 2A). Three-hour PCP treatment suppressed Trk phosphorylation in all doses tested. Six hours after PCP application, 1-25 μM doses achieved significant inhibition of Trk phosphorylation (Fig. 2A). When alterations in cell surface expression of the TrkB receptor were examined, we confirmed that PCP (10 μM) did not change the amount of surface TrkB, while the ligand BDNF indeed reduced surface TrkB levels (Ji et al. 2010) (Fig. 2B). As shown in Figure 2C,D, activation of Akt (a component of the PI3K pathway) and ERK1/2 (MAPK pathway) were also

Figure 1. PCP increased levels of intracellular BDNF in cultured cortical neurons. (A) BDNF levels (14 kD, mature BDNF) in total lysate were rapidly increased after PCP treatment, whereas expression levels of TrkB and p75 were unchanged. Cultured cortical neurons at DIV 10 and 11 were treated with PCP at indicated doses. Samples were collected 3 or 6 h after PCP addition. TUJ1 and β-actin were represented as controls. (B) The mature BDNF expression was quantified. Data represent mean ± standard deviation (n = 6, obtained from 6 independent cultures. n indicates the number of experiments if not otherwise specified.). **$P < 0.01$, *$P < 0.05$ versus con (without PCP). Statistical significance was evaluated by one-way ANOVA followed by Scheffe's post hoc test. (C) Size of cell body area was not changed by PCP. After 48 h of PCP (10 μM) treatment, neuronal cell body sizes were measured (con: n = 13; PCP: n = 12, n indicates the number of neurons in each experimental condition). (D) Immunocytochemistry revealed a significant increase in BDNF immunoreactivity in cortical neurons in PCP-treated cultures. Cells were immunostained with anti-BDNF and anti-MAP2 antibodies. PCP (1 μM) was applied for 3 h. Left: images after staining with anti-BDNF antibody (green). Bar = 50 μm. Middle: magnified images of insets in Left panels. Right: double staining with anti-BDNF (green) and anti-MAP2 (red) antibodies. Typical BDNF-containing vesicles are indicated by arrowheads. Bar = 10 μm. (E) Quantification of BDNF immunoreactivity. Mean intensity of BDNF immunoreactivity in one or two areas of cell body per 1 cell (around 200 μm²) and in 4–6 primary dendrites (around 50 μm²) were measured (cell body: con, n = 20 and PCP, n = 22; primary dendrite: con, n = 95 and PCP, n = 80; n indicates the number of areas obtained from 14 randomly selected neurons in 4 different dishes of the same culture preparation). ***$P < 0.001$ (t-test).

decreased by PCP (e.g., PCP 1 μM, 3 h: phosphorylated Akt: 62.9 ± 11.7% of control, $P < 0.001$; phosphorylated ERK1: 61.4 ± 6.7% of control, $P < 0.01$, phosphorylated ERK2: 51.6 ± 10.3% of control, $P < 0.01$), whereas expression of total Akt and ERK1/2 were intact. The reduced activation of Akt and ERK1/2 were maintained until 6 h after PCP treatment (Fig. 2C,D). To elucidate which Trk receptor (i.e., TrkA, TrkB, or TrkC) is responsible for the activation of intracellular signaling, cortical neurons were treated with various neurotrophins (Fig. 2E,F). BDNF and neurotrophin 4/5 (NT-4/5), both of which are specific ligands for TrkB, strongly activated Trk receptors, Akt and ERK1/2, whereas nerve growth factor (NGF, a specific ligand for TrkA) did not. NT-3 (for TrkC, and weakly for TrkA and TrkB) also demonstrated low activation ability. These data suggest that TrkB signaling is responsible for the activation of Akt and ERK1/2 pathways in our cultures.

Impaired Secretion of BDNF Caused by PCP

In cortical neurons, intracellular BDNF was increased following PCP exposure, whereas activation of Trk and downstream signaling cascades were decreased. To examine whether BDNF secretion was affected by PCP, conditioned medium of cultures incubated in the presence of anti-BDNF antibody was collected. The immunoprecipitated BDNF using conditioned media

showed the same molecular weight as that of recombinant mature BDNF in Western blot analysis, and we found reduced amounts of secreted BDNF after PCP exposure (1 μM, 6 h, Fig. 3A). A significant reduction in the secreted BDNF was observed (60.7 ± 9.9% of control, $P < 0.001$) in PCP-treated cultures (Fig. 3B). Such reduction in immunoprecipitated BDNF was further confirmed by enzyme-linked immunosorbent assay (ELISA) (Fig. 3C). Furthermore, we examined BDNF secretion in acute cortical slices and found significant suppression in the amount of secreted BDNF caused by PCP (1 μM, 3 h, Supplementary Fig. 3). It is well known that secretion of BDNF depends on neuronal activity (Hartmann et al. 2001; Lessmann et al. 2003). We tested the effect of glutamate (excitatory neurotransmitter) and tetrodotoxin (Na^+ channels blocker) on BDNF secretion in cultured neurons. As expected, increased BDNF by glutamate and decreased BDNF by TTX in conditioned media were observed (glutamate: 395 ± 114% of control, $P < 0.001$; TTX 49.1 ± 21.0% of control, $P < 0.001$) (Fig. 3D,E). These data suggest that PCP repressed the activity-dependent secretion of BDNF from cortical neurons.

Exposure to PCP for 48 h Did Not Affect Neuronal Viability

How does the suppression of BDNF/Trk signaling induced by PCP influence cortical neurons at the cellular and neuronal

Figure 2. PCP decreased activation of Trk receptors, MAPK/ERK1/2 and PI3K/Akt pathways. (A) Phosphorylation of Trk receptors was suppressed after PCP treatment for 3 and 6 h. Cell lysates were immunoprecipitated with anti-Trk antibody. For immunoblotting, anti-phospho-Tyr (pTyr) or anti-TrkB antibodies were used. Phosphorylated Trk receptors (pTrk) were quantified (3 h: $n = 10$; 6 h: $n = 6$, obtained from 5 independent cultures). ***$P < 0.001$, **$P < 0.01$, *$P < 0.05$ versus con (one-way ANOVA followed by Scheffe's post hoc test). (B) The amount of TrkB receptors on the cell surface after PCP (10 μM) treatment for 3 or 6 h was shown. Note that BDNF (100 ng/mL, positive control for TrkB internalization) exposure decreased surface expression of TrkB while PCP did not. ***$P < 0.001$ versus con. (C,D) Activation of Akt (a component of the PI3K pathway) and ERK1/2 (MAPK pathway) were reduced up to 6 h after PCP addition. Quantification of phosphorylated Akt (pAkt) (C) and ERK1/2 (pERK1/2) (D) was conducted ($n = 4$, respectively. Obtained from 4 independent cultures). ***$P < 0.001$, **$P < 0.01$, *$P < 0.05$ versus con. (E,F) Trk signaling in cortical neurons stimulated by various neurotrophins. (E) Following immunoprecipitation with anti-Trk antibody, immunoblotting with anti-pTyr and TrkB antibodies was performed. Each neurotrophin was applied at 100 ng/mL. Note that BDNF and NT-4/5 significantly stimulated Trk receptors in cortical neurons. (F) PI3K/Akt (Left) and MAPK/ERK1/2 (Right) pathways.

network level? To approach this issue, the survival of neurons after exposure to PCP was examined. After 48 h of exposure to 1 μM PCP, cortical neurons were immunostained with anti-MAP2 antibody (Fig. 4A). Quantified data of MAP2-positive living cells revealed no difference in neuronal survival between control and PCP-treated cultures (Fig. 4B). MTT assay also indicated that PCP (0.1–25 μM, 48 h) treatment did not affect cell viability (Fig. 4C). As shown in Fig. 4D, expression of Bcl-2, an antiapoptotic protein, and Bad, a proapoptotic protein, were unchanged by PCP (1 μM, 48 h).

PCP Diminished the Number of Presynaptic Sites and Synaptic Transmission

We next investigated the effect of PCP (48 h) on synaptic function. Western blot analysis revealed decreased expression of presynaptic proteins (synaptotagmin and synaptosome-

associated protein of 25 kD [SNAP25]) and postsynaptic glutamate receptors (NR2B and GluR1) (Fig. 5A). Immunostaining with anti-synaptotagmin antibody also demonstrated a decrease in the number of presynaptic puncta after PCP (1 μM, 48 h) exposure (13.8 ± 2.9 per 50 μm of dendrite in control and 8.3 ± 3.0 in PCP, $P < 0.001$) (Fig. 5B,C). Importantly, basal and depolarization-induced release of glutamate were both decreased after 48 h of PCP treatment (Fig. 5D), suggesting that PCP decreases the number of glutamatergic synapses. Electrophysiological recordings on cultured cortical neurons revealed that PCP (1 μM, 48 h) reduced the frequency of mEPSCs in both NMDA receptor and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor components (Fig. 6A,B). Cumulative plots also indicated a shift to longer intervals in both AMPA receptor- and NMDA receptor-mediated mEPSCs after PCP treatment (Fig. 6C), while the amplitude of mEPSCs was not changed (Fig. 6D).

Figure 3. PCP decreased secretion of BDNF from cortical neurons. Secreted BDNF into culture medium was immunoprecipitated with anti-BDNF antibody. In the presence of anti-BDNF antibody (2 µg/mL), cortical neurons were incubated with or without PCP at 1 µM for 6 h, followed by immunoprecipitation. A representative Western blot (A) and quantified data (B) were shown (n = 12, from 5 independent cultures). ***P < 0.001 versus con (t-test). rBDNF: recombinant BDNF; total: total lysates (10% input). (C) ELISA analysis also showed a decreased amount of BDNF secretion by PCP (con: n = 11; PCP: n = 12, n indicates the number of dishes for each experimental condition). (D, E) Glutamate increased secretion of BDNF while TTX decreased it. Cortical neurons were treated with glutamate (1 µM, 15 min) (D) or TTX (3 µM, 6 h) (E). (Glutamate: n = 6, TTX: n = 5, from 5 independent cultures, respectively). ***P < 0.001 versus con (t-test).

Exogenous BDNF Prevented PCP's Suppression of Intracellular Signaling and Synaptic Protein Expression

We investigated whether coapplication of BDNF with PCP could prevent the reduction in ERK1/2 and Akt activation at 3 h later as well as prevent the decrease in synaptic protein expression at 48 h later. As expected, exogenous BDNF (10 ng/mL) completely prevented the reduction of intracellular signaling (ERK 1/2 and Akt activation, Fig. 7A) and of synaptic proteins (synaptotagmin, SNAP25, NR2B, and GluR1, Fig. 7B). Delayed BDNF application at 3 h after PCP addition also prevented down regulation of synaptic proteins caused by PCP (Supplementary Fig. 4). These data suggest that the PCP-induced loss of synaptic connectivity is due to the impaired secretion of endogenous BDNF.

PCP Blocked Intracellular Ca²⁺ Mobilization and Other NMDA Receptor Antagonists Induced Intracellular BDNF Increase

Increase in the intracellular Ca^{2+} concentration is required for the activity-dependent secretion of BDNF (Hartmann et al.

Figure 4. PCP did not affect neuronal viability. (A) Forty-eight hours after PCP (1 µM) treatment, cortical neurons were stained with anti-MAP2 antibody. Bar = 50 µm. (B) These MAP2-positive cells were counted (n = 18, n indicates the number of randomly selected 250 × 250 µm² fields from 5 dishes for each experimental condition). (C) PCP (0.1–25 µM, 48 h) treatment did not affect the cell viability, which was determined by MTT assay (n = 4). Normalization to control was carried out. (D) Both Bcl-2 (an antiapoptotic protein) and Bad (a proapoptotic protein) levels were not altered by PCP (1 µM, 48 h) (n = 4). TUJ1 is represented as control.

2001; Lessmann et al. 2003). Thus, we assessed the possibility that the PCP-suppressed BDNF secretion is due to an inhibition of Ca^{2+} influx mediated by glutamate receptors. First, as shown in Fig. 8A, change in levels of glutamate receptors including NR2A, NR2B, and GluR1 during in vitro maturation were determined. We found that these proteins gradually increased during in vitro maturation, while very low expression levels at DIV 4 and 5 occurred (Fig. 8A). Synaptotagmin and SNAP25, presynaptic proteins, also increased during in vitro maturation in our cultures. Previously, we reported that cultured cortical neurons develop spontaneous Ca^{2+} oscillations during in vitro maturation, and the endogenous phenomenon is mediated via glutamatergic neurotransmission (Numakawa et al. 2002). Therefore, we determined whether PCP affected spontaneous Ca^{2+} oscillations at DIV 12 and found that PCP treatment (1 µM, 3 h) dramatically reduced the endogenous Ca^{2+} activity (Fig. 8B,C). In some cases, we observed a resting series of sister

Figure 5. PCP reduced the number of synaptic sites, expression of synaptic proteins, and release of glutamate. (A) The amount of synaptic proteins, including synaptotagmin, SNAP25, NR2B, and GluR1, were reduced by PCP. Samples were collected and analyzed after 48 h PCP (0.1–25 μM) treatment. ***$P < 0.001$, **$P < 0.01$, *$P < 0.05$ versus con (one-way ANOVA followed by Scheffe's post hoc test). ($n = 7$, from 5 independent cultures.) (B) The number of presynaptic sites was decreased by PCP (1 μM, 48 h). Representative images after synaptotagmin (red) and MAP2 (green) immunostaining are shown. Left: Bar = 50 μm, Right: inset in Left panels was magnified. Bar = 10 μm. (C) Synaptotagmin-positive presynaptic sites were counted. Thirty-eight randomly selected primary dendrites (per 50 μm) from 14 neurons in 4 randomly selected dishes for each experimental condition were selected. ***$P < 0.001$ versus con (t-test). (D) Glutamate release from cultured neurons was diminished by exposure to PCP. Glutamate from cortical cultures was collected for 1 min as nonstimulated basal and as high potassium-stimulated release. HK+; high potassium (KCl, 50 mM) condition. ***$P < 0.001$, ###$P < 0.001$ (t-test). $n = 6$. n indicates the number of dishes for each experimental condition.


Figure 6. PCP decreased the frequency (but not amplitude) of mEPSCs. Cortical cultures were exposed to PCP (1 μM, 48 h), followed by recording of mEPSCs. (A) AMPA component of mEPSCs (AMPA-mEPSC) was recorded in control- and PCP-treated neurons in the presence of D-APV (25 μM) (Left). NMDA component of mEPSPs (NMDA-mEPSC) in both control and PCP conditions in the presence of CNQX (5 μM) with Mg^{2+} free was also measured (Right). Typical mEPSC for each condition (arrowhead) are shown in the inset. (B) Mean mEPSC frequency for control cells and PCP-treated cells. Error bars represent SEM. **$P < 0.05$ (t-test). (C) Cumulative probability histogram for inter-AMPA-mEPSC (Left) and inter-NMDA-mEPSC intervals (Right) from control (thin) and PCP treatments (solid). Each data point represents the mean from 5 cells. (D) Mean amplitude of mEPSC in control and in PCP treatments. n indicates the number of cells obtained from 6 to 10 independent cultures.

Figure 7. Exogenous BDNF prevented down regulation of intracellular signaling and synaptic protein expression. BDNF (10 ng/mL) was added immediately after PCP (10 μM) application. (A) Exogenous BDNF prevented the negative effect of PCP on ERK 1/2 and Akt activation. Samples were collected at 3 h after PCP application. ($n = 4$, from 2 independent cultures.) $**P < 0.01$, $*P < 0.05$ versus con; $###P < 0.001$, $##P < 0.01$, $#P < 0.05$ versus PCP (one-way ANOVA followed by Scheffe's post hoc test). (B) Decrease in levels of synaptic proteins, including synaptotagmin, SNAP25, NR2B, and GluR1 after PCP treatment (10 μM, 48 h) did not occur in the presence of BDNF (10 ng/mL). TUJ1 and β-actin are controls. ($n = 5$, from 3 independent cultures.) $***P < 0.001$, $**P < 0.01$, $*P < 0.05$ versus con; $###P < 0.001$, $##P < 0.01$ versus PCP (one-way ANOVA followed by Scheffe's post hoc test).


Figure 8. PCP inhibited intracellular Ca^{2+} elevation in mature cortical neurons. (A) Developmental change in the expression of glutamate receptors (NR2A, NR2B, and GluR1), in addition to synaptotagmin and SNAP25, were shown. Expression of these synaptic proteins was gradually increased during in vitro maturation and reached maximum levels around DIV 10. ($n = 3$, from 3 independent cultures). TUJ1 and β-actin are controls. (B) Spontaneous Ca^{2+} oscillations were decreased in cultured cortical neurons in the presence of PCP (1 μM, 3 h). Traces were obtained from 3 neurons at DIV 12 in the same dish for each condition. The fluorescence ratio (F/F_0, F_0; basal intensity) was calculated. (C) The number of the frequency in Ca^{2+} oscillations was counted. ($n = 6$, n indicates the number of dishes of a sister culture). $***P < 0.001$ versus con. (D) Glutamate-triggered intracellular Ca^{2+} elevation was blocked by PCP. PCP (1 μM) was applied 3 h before glutamate (1 μM) stimulation. DIV 12. (E) Quantified data of the evoked Ca^{2+} in the presence or the absence of PCP at DIV 5 or at DIV 12. Summarized data from 50 randomly selected cells for each experimental condition. $***P < 0.001$ versus con. (one-way ANOVA followed by Scheffe's post hoc test).

cultures, in which all neurons showed no Ca^{2+} oscillations as previously reported (Numakawa et al. 2002). Then, the glutamate-evoked increase in intracellular Ca^{2+} concentration was also checked using such resting neurons (Fig. 8D,E and Supplementary Fig. 5A). Importantly, PCP treatment for 3 h repressed the glutamate-stimulated Ca^{2+} (Fig. 8D,E and Supplementary Fig. 5A). Such suppression of Ca^{2+} elevation was still observed at 6 h after PCP addition (Supplementary Fig. 5B). In line with the low expression level of glutamate receptors, immature neurons at DIV 5 did not respond to glutamate with or without PCP (Fig. 8E). In the DIV 5 immature neurons, PCP had no effect on intracellular BDNF expression (Supplementary Table 1). Furthermore, we confirmed a positive effect of other noncompetitive and competitive antagonists for NMDA receptors (MK-801 and APV, respectively) on intracellular BDNF levels in DIV 12 neurons (but not in DIV 5 neurons) (Supplementary Table 2), indicating that the effect is not specific to PCP but it holds true for NMDA receptor antagonists in general. These results suggest that inhibition of Ca^{2+} influx via NMDA receptors was involved in the decrease in BDNF secretion by PCP.

Discussion

In the present study, we found that intracellular BDNF protein was transiently increased by 3-h PCP exposure. Despite such a BDNF increase, activation of Trks and downstream signaling pathways (ERK1/2 and Akt) were diminished. Importantly, the number of synaptic sites and expression of synaptic proteins were reduced 48 h after PCP application. Furthermore, both basal and depolarization-evoked glutamate release were decreased in PCP-treated neurons, and the electrophysiological studies also revealed a reduced frequency of mEPSCs by PCP. Interestingly, we discovered suppression in BDNF secretion after PCP treatment both in cortical cultures and acute slices. Application of exogenous BDNF prevented the PCP-induced reduction in expression of synaptic proteins in cortical cultures. It is possible that the PCP-induced impairment of BDNF secretion results in the transient accumulation of intracellular BDNF and leads to down regulation of BDNF/TrkB signaling, which is required for maintenance of synaptic protein expression. As PCP treatment significantly inhibited the spontaneous Ca^{2+} activity and evoked Ca^{2+} influx by glutamate, the inhibition of Ca^{2+} mobilization may contribute to the PCP-induced impairment of BDNF secretion.

In hippocampal and cortical neurons, BDNF showed a vesicular expression pattern in dendrites and axons and appeared to be sorted into a regulated pathway in which BDNF is secreted in response to neuronal activity (Goodman et al. 1996; Farhadi et al. 2000; Hartmann et al. 2001 Kojima et al. 2001; Kohara et al. 2001; Gartner and Staiger 2002; Lessmann et al. 2003; Wu et al. 2004; Adachi et al. 2005). The activity-dependent secretion of BDNF is triggered by an increase in intracellular Ca^{2+} concentration via ionotropic glutamate receptors, voltage-gated Ca^{2+} channels, and internal Ca^{2+} stores (Hartmann et al. 2001; Lessmann et al. 2003). In the present study, we examined the possibility that PCP attenuated an increase of intracellular Ca^{2+} concentration at basal and evoked conditions, contributing to the transient increase of intracellular BDNF and suppression of its secretion. In mature cortical neurons, we found that PCP induced an inhibition of Ca^{2+} mobilization, and that BDNF protein released into the culture

medium was reduced after PCP application compared with control. This reduction in BDNF secretion was demonstrated by both immunoblotting and ELISA methods after immunoprecipitation with anti-BDNF antibody. Interestingly, when we examined the effect of PCP on de novo synthesis of BDNF, we found decreased levels of BDNF mRNA (Supplementary Fig. 1B), suggesting that PCP-dependent BDNF increase is not due to transcriptional activity. Resultant down regulation of BDNF protein levels might appear as a reduction in the amount of intracellular BDNF at 6 h or later. Importantly, other NMDA antagonists, MK-801 (noncompetitive) and APV (competitive), also elevated BDNF levels in neurons, suggesting that the PCP-increased BDNF would be due to the inhibitory effect of PCP on NMDA receptors. Furthermore, such an increase of BDNF by NMDA antagonists occurred only in mature cortical neurons (DIV 12) that express adequate glutamate receptors. PCP-dependent impairment of BDNF secretion and subsequent decrease in synaptic function may only occur in mature fully developed neurons that express adequate NMDA receptors.

The reduction of BDNF secretion is considered to be a neuronal response to PCP, as we confirmed that the majority of cultured cells in the experiment were indeed neurons. Furthermore, PCP did not cause an intracellular increase of BDNF in pure astroglial cultures. In our cortical cultures, vesicular expression of BDNF was observed only in GAD-negative neurons. If this vesicular pattern of BDNF expression reflects the activity-dependent population of BDNF secretion, it is possible that PCP specifically impacts the regulatory release of BDNF from glutamatergic (not GAD-positive) neurons. Importantly, some reports suggest that preferential binding of PCP to NMDA receptors on GABAergic interneurons results in the activation of glutamatergic pyramidal neurons in vivo (Homayoun and Moghaddam 2007; Kargieman et al. 2007). Homayoun and Moghaddam reported that firing rates in ~69% of GABAergic neurons and 86% of pyramidal neurons were decreased after PCP injection (Homayoun and Moghaddam 2007). Interestingly, Kargieman et al. showed that PCP increases and decreases the activity of 45% and 33% of the pyramidal neurons, respectively (Kargieman et al. 2007). Our results indicated a decreased synaptic activity in cultured cortical neurons after 48 h PCP exposure. Furthermore, PCP-dependent decrease in the secretion of BDNF from acute cortical slices, in which local neuronal circuits remain intact, was confirmed. It is possible that differences in experimental conditions including dose of PCP and neuronal maturity may influence such a different neuronal response to PCP, although future studies will be needed using in vivo and in vitro systems.

Secretion of BDNF to the extracellular space is required to generate its biological effects via activation of TrkB. Indeed, activation of Trk receptors and downstream signaling cascades (ERK1/2 and Akt) were reduced by PCP. In our system, BDNF and NT-4/5 functioned as major contributors for the activation of Trk receptors, suggesting that TrkB signaling is predominant. A subset of the BDNF/TrkB downstream signaling molecules, especially ERK1/2 activity, is known to be regulated by NMDA receptor-mediated Ca^{2+} influx (Xia et al. 1996; Sutton and Chandler 2002). Therefore, it is possible that decreased activity of ERK1/2 may be attributable, at least in part, to the blockade of the NMDA receptor by PCP directly. However, simultaneous application of exogenous BDNF blocked the PCP-dependent suppression of synaptic protein levels as well as ERK1/2 and Akt signaling pathways even when NMDA receptors were

blocked in the presence of PCP. Recently, we reported that ERK1/2 activity is involved in the maintenance of synaptic protein expression (Kumamaru et al. 2011). Furthermore, delayed application of exogenous BDNF reversed the suppression of some synaptic proteins inhibited by PCP. All things considered, impaired BDNF secretion substantially contributed to the down regulation of ERK1/2 activity and synaptic protein expression.

The number of synaptic sites was decreased when chronic PCP exposure was administered. There are 2 lines of evidence: 1) the reduced expression of pre- and postsynaptic proteins assessed with Western blotting and 2) the decreased number of presynaptic sites estimated with immunostaining. We also obtained evidence for functional changes, showing a marked reduction in glutamate release as well as a decreased frequency of mEPSCs mediated by NMDA and AMPA receptors. Taken together, excitatory neurotransmission is suppressed by 48 h of PCP treatment.

It is well known that BDNF/TrkB signaling plays an important role in synaptic plasticity. BDNF stabilizes and increases dendritic synapse density in the optic tectum (Hu et al. 2005; Sanchez et al. 2006). BDNF increases spine density in hippocampal neurons through ERK1/2 activation (Alonso et al. 2004). We also reported that BDNF increases the expression of pre- and postsynaptic proteins via ERK1/2 signaling in cultured cortical neurons (Kumamaru et al. 2011). Overexpression of TrkB or activation of PI3K/Akt signaling enhances motility of dendritic filopodia and synaptic density (Luikart et al. 2008). These findings, including our current results, suggest that decreased BDNF secretion caused by PCP is one of the major factors for loss of synaptic connections and/or overall neuronal function.

In the present study, 48 h of PCP treatment did not change both the number of MAP2-positive cells and mitochondrial activity in cortical cultures. Mitochondrial activity was not influenced even when a critically high concentration of PCP (25 μM) was applied. Furthermore, expression levels of both an antiapoptotic protein Bcl-2 and a proapoptotic protein Bad were unchanged after PCP application. These data suggest that PCP has no major influence on survival of cultured cortical neurons, although it does inhibit synaptic connectivity and function. Interestingly, Lei et al. (2008) reported that PCP causes apoptosis in cultured cortical neurons through suppression of Akt activity and activation of GSK3β and caspase-3. This discrepancy between Lei et al. (2008) and our study may be attributable to differences in culture conditions, as their neurobasal medium contained B27 while our 5/5 DF medium contained serums.

PCP induces schizophrenia-like behaviors in humans (Allen and Young 1978; Javitt and Zukin 1991) and rodents (Noda et al. 1995; Furuta and Kunugi 2008). In vivo administration of PCP causes extensive reduction in the number of spines in the rat prefrontal cortex (Hajszan et al. 2006) and suppression of glutamate release in the prefrontal cortex of mice (Nabeshima et al. 2006; Murai et al. 2007). Postmortem brain studies from schizophrenia patients demonstrate that the number of neurons in the prefrontal cortex is not decreased (Pakkenberg 1993; Akbarian et al. 1995), although synaptophysin immunoreactivity and dendritic spine density of pyramidal cells are reduced (Glantz and Lewis 1997; Glantz and Lewis 2000; Knable et al. 2004). These findings are consistent with our observation of synaptic loss and decreased glutamatergic

transmission without any change in cell viability in PCP-treated cortical neurons. Therefore, impairment in BDNF secretion and downstream signaling may be involved in the pathogenesis of schizophrenia-like behaviors. In fact, altered expression of BDNF and TrkB has been reported in postmortem brains of schizophrenia patients in several studies (e.g., Takahashi et al. 2000; Durany et al. 2001; Weickert et al. 2003; Weickert et al. 2005; Hashimoto et al. 2005; Altar et al. 2009). Recently, biological functions of proneurotrophins through the p75 receptor were revealed (Lee et al. 2001; Dechant and Barde 2002; Pagadala et al. 2006). Considering this, it may be valuable to study not only TrkB-stimulated signaling but also p75-stimulated signaling, during PCP exposure.

In conclusion, our results suggest that impaired secretion of BDNF and the resultant decrease in activation of Trk receptor signaling pathways are responsible, at least in part, for the PCP-dependent reduction in synaptic connectivity and function, which may be involved in PCP's ability to elicit schizophrenia-like behaviors. Our experimental system might be a "cell model" suitable for studies to clarify the molecular mechanisms of schizophrenia.

Supplementary Material

Supplementary material can be found at: http://www.cercor. oxfordjournals.org/

Notes

References

Adachi N, Kohara K, Tsumoto T. 2005. Difference in trafficking of brain-derived neurotrophic factor between axons and dendrites of cortical neurons, revealed by live-cell imaging. BMC Neurosci. 6:42-52.

Akbarian S, Kim JJ, Potkin SG, Hagman JO, Tafazzoli A, Bunney WE Jr, Jones EG. 1995. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry. 52:258-266.

Allen RM, Young SJ. 1978. Phencyclidine-induced psychosis. Am J Psychiatry. 135:1081-1084.

Alonso M, Medina JH, Pozzo-Miller L. 2004. ERK1/2 activation is necessary for BDNF to increase dendritic spine density in hippocampal CA1 pyramidal neurons. Learn Mem. 11:172-178.

Altar CA. 1999. Neurotrophins and depression. Trends Pharmacol Sci. 20:59-61.

Altar CA, Vawter MP, Ginsberg SD. 2009. Target identification for CNS diseases by transcriptional profiling. Neuropsychopharmacology. 34:18-54.

Andreasen NC. 1995. Symptoms, signs, and diagnosis of schizophrenia. Lancet. 346:477-481.

Angelucci F, Brenè S, Mathé AA. 2005. BDNF in schizophrenia, depression and corresponding animal models. Mol Psychiatry. 10:345-352.

Arancio O, Chao MV. 2007. Neurotrophins, synaptic plasticity and dementia. Curr Opin Neurobiol. 17:325-330.

Chen WG, Chang Q, Lin Y, Meissner A, West AE, Griffith EC, Jaenisch R, Greenberg ME. 2003. Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science. 302:885-889.

Conner JM, Lauterborn JC, Yan Q, Gall C, Varon S. 1997. Distribution of brain-derived neurotrophic factor (BDNF) protein and mRNA in the normal adult rat CNS: evidence for anterograde axonal transport. J Neurosci. 17:2295-2313.

Danysz W, Wroblewski JT, Costa E. 1988. Learning impairment in rats by N-methyl-D-aspartate receptor antagonists. Neuropharmacology. 27:653-656.

Davis MI. 2008. Ethanol-BDNF interactions: still more questions than answers. Pharmacol Ther. 118:36-57.

Dechant G, Barde YA. 2002. The neurotrophin receptor p75(NTR): novel functions and implications for diseases of the nervous system. Nat Neurosci. 5:1131-1136.

Durany N, Miche T, Zochling R, Boissl KW, Cruz-Sanchez FF, Riederer P, Thome J. 2001. Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr Res. 52:79-86.

Durany N, Thome J. 2004. Neurotrophic factors and the pathophysiology of schizophrenic psychoses. Eur Psychiatry. 19:326-337.

Ernfors P, Wetmore C, Olson L, Persson H. 1990. Identification of cells in rat brain and peripheral tissues expressing mRNA for members of the nerve growth factor family. Neuron. 5:511-526.

Farhadi HF, Mowla SJ, Petrecca K, Morris SJ, Seidah NG, Murphy RA. 2000. Neurotrophin-3 sorts to the constitutive secretory pathway of hippocampal neurons and is diverted to the regulated secretory pathway by coexpression with brain-derived neurotrophic factor. J Neurosci. 20:4059-4068.

Frankle WG, Lerma J, Laruelle M. 2003. The synaptic hypothesis of schizophrenia. Neuron. 39:205-216.

Furuta M, Kunugi H. 2008. Animal models for sdhizophrenia: a brief overview. In: Truck CW, editor. Biomarkers for psychiatric disorders. New York: Springer. p. 163-184.

Gartner A, Staiger V. 2002. Neurotrophin secretion from hippocampal neurons evoked by long-term-potentiation-inducing electrical stimulation patterns. Proc Natl Acad Sci U S A. 99:6386-6391.

Gauthier LR, Charrin BC, Borrell-Pagès M, Dompierre JP, Rangone H, Cordelières FP, De Mey J, MacDonald ME, Lessmann V, Humbert S, et al. 2004. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell. 118:127-138.

Glantz LA, Lewis DA. 1997. Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia. Regional and diagnostic specificity. Arch Gen Psychiatry. 54:943-952.

Glantz LA, Lewis DA. 2000. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry. 57:65-73.

Goodman LJ, Valverde J, Lim F, Geschwind MD, Federoff HJ, Geller AI, Hefti F. 1996. Regulated release and polarized localization of brain-derived neurotrophic factor in hippocampal neurons. Mol Cell Neurosci. 7:223-228.

Hajszan T, Leranth C, Roth RH. 2006. Subchronic phencyclidine treatment decreases the number of dendritic spine synapses in the rat prefrontal cortex. Biol Psychiatry. 60:639-644.

Handelmann GE, Contreras PC, O'Donohue TL. 1987. Selective memory impairment by phencyclidine in rats. Eur J Pharmacol. 140:69-73.

Harrison PJ, Weinberger DR. 2005. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry. 10:40-68.

Harte MK, Cahir M, Reynolds GP, Gartlon JE, Jones DN. 2007. Sub-chronic phencyclidine administration increases brain-derived neurotrophic factor in the RAT hippocampus. Schizophr Res. 94:371-372.

Hartmann M, Heumann R, Lessmann V. 2001. Synaptic secretion of BDNF after high-frequency stimulation of glutamatergic synapses. EMBO J. 20:5887-5897.

Hashimoto R, Numakawa T, Ohnishi T, Kumamaru E, Yagasaki Y, Ishimoto T, Mori T, Nemoto K, Adachi N, Izumi A, et al. 2006. Impact of the DISC1 Ser704Cys polymorphism on risk for major depression, brain morphology and ERK signaling. Hum Mol Genet. 15:3024-3033.

Hashimoto T, Bergen SE, Nguyen QL, Xu B, Monteggia LM, Pierri JN, Sun Z, Sampson AR, Lewis DA. 2005. Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. J Neurosci. 25:372-383.

Hatanaka H, Tsukui H, Nihonmatsu I. 1988. Developmental change in the nerve growth factor action from induction of choline acetyltransferase to promotion of cell survival in cultured basal forebrain cholinergic neurons from postnatal rats. Brain Res. 467:85-95.

Hofer M, Pagliusi SR, Hohn A, Leibrock J, Barde YA. 1990. Regional distribution of brain-derived neurotrophic factor mRNA in the adult mouse brain. EMBO J. 9:2459-2464.

Homayoun H, Moghaddam B. 2007. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci. 27:11496-11500.

Hu B, Nikolakopoulou AM, Cohen-Cory S. 2005. BDNF stabilizes synapses and maintains the structural complexity of optic axons in vivo. Development. 132:4285-4298.

Javitt DC, Zukin SR. 1991. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 148:1301-1308.

Jentsch JD, Roth RH. 1999. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 20:201-225.

Ji Y, Lu Y, Yang F, Shen W, Tang TT, Feng L, Duan S, Lu B. 2010. Acute and gradual increases in BDNF concentration elicit distinct signaling and functions in neurons. Nat Neurosci. 13:302-309.

Kalinichev M, Robbins MJ, Hartfield EM, Maycox PR, Moore SH, Savage KM, Austin NE, Jones DN. 2008. Comparison between intraperitoneal and subcutaneous phencyclidine administration in Sprague-Dawley rats: a locomotor activity and gene induction study. Prog Neuropsychopharmacol Biol Psychiatry. 32:414-422.

Kargieman L, Santana N, Mengod G, Celada P, Artigas F. 2007. Antipsychotic drugs reverse the disruption in prefrontal cortex function produced by NMDA receptor blockade with phencyclidine. Proc Natl Acad Sci U S A. 104:14843-14848.

Katoh-Semba R, Takeuchi IK, Semba R, Kato K. 1997. Distribution of brain-derived neurotrophic factor in rats and its changes with development in the brain. J Neurochem. 69:34-42.

Kesner RP, Hardy JD, Novak JM. 1983. Phencyclidine and behavior: II. active avoidance learning and radial arm maze performance. Pharmacol Biochem Behav. 18:351-356.

Knable MB, Barci BM, Webster MJ, Meador-Woodruff J, Torrey EF, Stanley Neuropathology Consortium 2004. Molecular abnormalities of the hippocampus in severe psychiatric illness: postmortem findings from the Stanley Neuropathology Consortium. Mol Psychiatry. 9:609-620.

Kohara K, Kitamura A, Morishima M, Tsumoto T. 2001. Activity-dependent transfer of brain-derived neurotrophic factor to postsynaptic neurons. Science. 291:2419-2423.

Kojima M, Takei N, Numakawa T, Ishikawa Y, Suzuki S, Matsumoto T, Katoh-Semba R, Nawa H, Hatanaka H. 2001. Biological characterization and optical imaging of brain-derived neurotrophic factor-green fluorescent protein suggest an activity dependent local release of brain-derived neurotrophic factor in neurites of cultured hippocampal neurons. J Neurosci Res. 64:1-10.

Kuczewski N, Porcher C, Lessmann V, Medina I, Gaiarsa JL. 2009. Activity-dependent dendritic release of BDNF and biological consequences. Mol Neurobiol. 39:37-49.

Kumamaru E, Numakawa T, Adachi N, Kunugi H. 2011. Glucocorticoid suppresses BDNF-stimulated MAPK/ERK pathway via inhibiting interaction of Shp2 with TrkB. FEBS Lett. 585:3224-3228.

Kunugi H, Ida I, Owashi T, Kimura M, Inoue Y, Nakagawa S, Yabana T, Urushibara T, Kanai R, Aihara M, et al. 2006. Assessment of the dexamethasone/CRH test as a state-dependent marker for hypothalamic-pituitary-adrenal (HPA) axis abnormalities in major depressive episode: a multicenter study. Neuropsychopharmacology. 31:212-220.

Lee R, Kermani P, Teng KK, Hempstead BL. 2001. Regulation of cell survival by secreted proneurotrophins. Science. 294:1945-1948.

Lei G, Xia Y, Johnson KM. 2008. The role of Akt-GSK-3beta signaling and synaptic strength in phencyclidine-induced neurodegeneration. Neuropsychopharmacology. 33:1343-1353.

Lessmann V, Gottmann K, Malcangio M. 2003. Neurotrophin secretion: current facts and future prospects. Prog Neurobiol. 69:341-374.

Lewis DA, Hashimoto T, Volk DW. 2005. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci. 6:312-324.

Lu B. 2003. BDNF and activity-dependent synaptic modulation. Learn Mem. 10:86-98.

Luikart BW, Zhang W, Wayman GA, Kwon CH, Westbrook GL, Parada LF. 2008. Neurotrophin-dependent dendritic filopodial motility: a convergence on PI3K signaling. J Neurosci. 28:7006-7012.

Mansbach RS, Geyer MA. 1989. Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. Neuropsychopharmacology. 2:299-308.

McCullumsmith RE, Clinton SM, Meador-Woodruff JH. 2004. Schizophrenia as a disorder of neuroplasticity. Int Rev Neurobiol. 59:19-45.

Mirnics K, Middleton FA, Lewis DA, Levitt P. 2001. Analysis of complex brain disorders with gene expression microarrays: schizophrenia as a disease of the synapse. Trends Neurosci. 24:479-486.

Murai R, Noda Y, Matsui K, Kamei H, Mouri A, Matsuba K, Nitta A, Furukawa H, Nabeshima T. 2007. Hypofunctional glutamatergic neurotransmission in the prefrontal cortex is involved in the emotional deficit induced by repeated treatment with phencyclidine in mice: implications for abnormalities of glutamate release and NMDA-CaMKII signaling. Behav Brain Res. 180:152-160.

Nabeshima T, Mouri A, Murai R, Noda Y. 2006. Animal model of schizophrenia: dysfunction of NMDA receptor-signaling in mice following withdrawal from repeated administration of phencyclidine. Ann N Y Acad Sci. 1086:160-168.

Nelson ED, Kavalali ET, Monteggia LM. 2008. Activity-dependent suppression of miniature neurotransmission through the regulation of DNA methylation. J Neurosci. 28:395-406.

Noda Y, Yamada K, Furukawa H, Nabeshima T. 1995. Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia. Br J Pharmacol. 116:2531-2537.

Numakawa T, Chiba S, Richards M, Wakabayashi C, Adachi N, Kunugi H. 2011. Production of BDNF by stimulation with antidepressant-related substances. J Biol Med. 3:1-10.

Numakawa T, Kumamaru E, Adachi N, Yagasaki Y, Izumi A, Kunugi H. 2009. Glucocorticoid receptor interaction with TrkB promotes BDNF-triggered PLC-gamma signaling for glutamate release via a glutamate transporter. Proc Natl Acad Sci U S A. 106:647-652.

Numakawa T, Yagasaki Y, Ishimoto T, Okada T, Suzuki T, Iwata N, Ozaki N, Taguchi T, Tatsumi M, Kamijima K, et al. 2004. Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia. Hum Mol Genet. 13:2699-2708.

Numakawa T, Yamagishi S, Adachi N, Matsumoto T, Yokomaku D, Yamada M, Hatanaka H. 2002. Brain-derived neurotrophic factor-induced potentiation of Ca(2+) oscillations in developing cortical neurons. J Biol Chem. 277:6520-6529.

Olney JW, Farber NB. 1995. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry. 52:998-1007.

Pagadala PC, Dvorak LA, Neet KE. 2006. Construction of a mutated pro-nerve growth factor resistant to degradation and suitable for biophysical and cellular utilization. Proc Natl Acad Sci U S A. 103:17939-17943.

Pakkenberg B. 1993. Total nerve cell number in neocortex in chronic schizophrenics and controls estimated using optical disectors. Biol Psychiatry. 34:768-772.

Sams-Dodd F. 1996. Phencyclidine-induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia. Behav Pharmacol. 7:3-23.

Sanchez AL, Matthews BJ, Meynard MM, Hu B, Javed S, Cohen Cory S. 2006. BDNF increases synapse density in dendrites of developing tectal neurons in vivo. Development. 133:2477-2486.

Semba J, Wakuta M, Suhara T. 2006. Different effects of chronic phencyclidine on brain-derived neurotrophic factor in neonatal and adult rat brains. Addict Biol. 11:126-130.

Stoop R, Poo MM. 1996. Synaptic modulation by neurotrophic factors: differential and synergistic effects of brain-derived neurotrophic factor and ciliary neurotrophic factor. J Neurosci. 16:3256-3264.

Sutton G, Chandler LJ. 2002. Activity-dependent NMDA receptor-mediated activation of protein kinase B/Akt in cortical neuronal cultures. J Neurochem. 82:1097-1105.

Takahashi M, Kakita A, Futamura T, Watanabe Y, Mizuno M, Sakimura K, Castren E, Nabeshima T, Someya T, Nawa H. 2006. Sustained brain-derived neurotrophic factor up-regulation and sensorimotor gating abnormality induced by postnatal exposure to phencyclidine: comparison with adult treatment. J Neurochem. 99:770-780.

Takahashi M, Shirakawa O, Toyooka K, Kitamura N, Hashimoto T, Maeda K, Koizumi S, Wakabayashi K, Takahashi H, Someya T, et al. 2000. Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Mol Psychiatry. 5:293-300.

Wass C, Archer T, Palsson E, Fejgin K, Klamer D, Engel JA, Svensson L. 2006. Effects of phencyclidine on spatial learning and memory: nitric oxide-dependent mechanisms. Behav Brain Res. 171:147-153.

Weickert CS, Hyde TM, Lipska BK, Herman MM, Weinberger DR, Kleinman JE. 2003. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol Psychiatry. 8:592-610.

Weickert CS, Ligons DL, Romanczyk T, Ungaro G, Hyde TM, Herman MM, Weinberger DR, Kleinman JE. 2005. Reductions in neurotrophin receptor mRNAs in the prefrontal cortex of patients with schizophrenia. Mol Psychiatry. 10:637-650.

Wu YJ, Krüttgen A, Möller JC, Shine D, Chan JR, Shooter EM, Cosgaya JM. 2004. Nerve growth factor, brain-derived neurotrophic factor, and neurotrophin-3 are sorted to dense-core vesicles and released via the regulated pathway in primary rat cortical neurons. J Neurosci Res. 75:825-834.

Xia Z, Dudek H, Miranti CK, Greenberg ME. 1996. Calcium influx via the NMDA receptor induces immediate early gene transcription by a MAP kinase/ERK-dependent mechanism. J Neurosci. 16:5425-5436.

Yan Q, Rosenfeld RD, Matheson CR, Hawkins N, Lopez OT, Bennett L, Welcher AA. 1997. Expression of brain-derived neurotrophic factor protein in the adult rat central nervous system. Neuroscience. 78:431-448.

Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, MacDonald ME, Friedlander RM, Silani V, Hayden MR, et al. 2001. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science. 293:493-498.

Elevated Cortisol Level and Cortisol/DHEAS Ratio in Schizophrenia as Revealed by Low-Dose Dexamethasone Suppression Test

Hiroaki Hori[*,1,3], Toshiya Teraishi[1], Daimei Sasayama[1], Takashi Fujii[1], Kotaro Hattori[1], Masanori Ishikawa[2] and Hiroshi Kunugi[1,3]

[1]*Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4-1-1, Ogawahigashi, Kodaira, Tokyo, 187-8502, Japan*

[2]*National Center of Neurology and Psychiatry Hospital, Tokyo, 187-8502, Japan*

[3]*CREST (Core Research of Evolutional Science & Technology), JST (Japan Science and Technology Agency), Tokyo, 102-0075, Japan*

Abstract: Earlier studies have used the dexamethasone (DEX) suppression test (DST) to investigate the hypothalamic-pituitary-adrenal (HPA) function in schizophrenia, although the findings are controversial. Recently there has been an increased interest in the role of dehydroepiandrosterone (DHEA) and its sulfate (DHEAS) in HPA axis function. Several studies have investigated basal DHEA(S) levels and cortisol/DHEA(S) ratios in schizophrenia patients, while no attempts have been made to investigate DHEA(S) level in response to the DEX administration. We aimed to compare the post-DEX cortisol and DHEAS levels and the cortisol/DHEAS ratio between schizophrenia patients and healthy controls. Here we administered the DST to 43 patients with schizophrenia and 37 age- and sex-matched healthy controls. Plasma cortisol levels, serum DHEAS levels, and cortisol/DHEAS ratio after administration of 0.5 mg of DEX were compared between the two groups. Schizophrenia patients showed significantly higher cortisol level and cortisol/DHEAS ratio than controls, while DHEAS levels were not significantly different between groups. These results suggest that besides the cortisol level, cortisol/DHEAS ratio as assessed with the DST might reflect abnormal HPA axis function in schizophrenia.

Keywords: Cortisol, dehydroepiandrosterone, dehydroepiandrosterone sulfate, dexamethasone suppression test, hypothalamic-pituitary-adrenal axis, schizophrenia.

INTRODUCTION

The hypothalamic-pituitary-adrenal (HPA) axis is activated by all sorts of stressors, and this fact has represented the rationale for investigations into HPA axis function in schizophrenia, a disorder where stress could play a pivotal role in its onset and exacerbation. A large number of earlier studies have used the dexamethasone (DEX) suppression test (DST) to explore negative feedback inhibition of cortisol in schizophrenia patients. The findings were, however, controversial such that the rate of non-suppression to the DST varied from 0% to 73% [1]. A meta-analysis of 26 DST studies [2] revealed that non-suppression rates of schizophrenia patients (19%) were significantly lower than those of patients with major depression (51%) and significantly higher than those of healthy controls (7%). Indeed, HPA axis dysfunction is less consistently reported in schizophrenia than in depression [3,4]. On the other hand, studies employing psychosocial challenge paradigms have reported blunted cortisol responses in schizophrenia patients [5,6]. Individuals who are at risk for developing psychosis [7,8], those with first episode psychosis [9,10], and those

with schizotypal personality [11,12] have also been shown to be associated with altered HPA axis function, although findings are again not uniform, that is, both hyper- and hypo-cortisolism are reported. All these findings indicate that although schizophrenia would be associated with altered HPA axis function, its precise nature is yet to be established. More recently, there has been an increasing interest in the role of dehydroepiandrosterone (DHEA) and its more stable sulphated conjugated metabolite, DHEAS, in the neuroendocrinology of schizophrenia.

Like cortisol, DHEA and DHEAS (herein jointly referred to as "DHEA(S)"), are secreted by the adrenal cortex, at least partly in response to adrenocorticotropin-releasing hormone. DHEAS is the most abundant adrenal steroid in humans and its serum concentration is much higher than DHEA. DHEA(S) has neuroprotective actions, and is a precursor to more potent androgens and estrogens, such as testosterone and estradiol [13]. DHEA(S) is also classified as a neurosteroid, meaning that this hormone does not only cross the blood brain barrier to exert effects within central nervous system (i.e., a neuroactive steroid) but is synthesized *de novo* in the brain from its sterol precursor [14]. DHEA(S) acts as a gamma-aminobutyric acid type A receptor antagonist and is shown to be involved in the regulation of neuronal survival and differentiation [15]. It is also shown to act as a sigma-1 receptor agonist [16].

*Address correspondence to this author at the Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4-1-1, Ogawahigashi, Kodaira, Tokyo, 187-8502, Japan; Tel: +81 42 341 2711; Fax +81 42 346 1744; E-mail: hori@ncnp.go.jp